WO1998035015A1 - Cyclin-dependent protein kinase - Google Patents

Cyclin-dependent protein kinase Download PDF

Info

Publication number
WO1998035015A1
WO1998035015A1 PCT/US1998/002337 US9802337W WO9835015A1 WO 1998035015 A1 WO1998035015 A1 WO 1998035015A1 US 9802337 W US9802337 W US 9802337W WO 9835015 A1 WO9835015 A1 WO 9835015A1
Authority
WO
WIPO (PCT)
Prior art keywords
leu
pro
ala
gly
glu
Prior art date
Application number
PCT/US1998/002337
Other languages
French (fr)
Inventor
David L. Gerhold
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9707491.8A external-priority patent/GB9707491D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to CA002280206A priority Critical patent/CA2280206A1/en
Priority to JP53492298A priority patent/JP2001511015A/en
Priority to EP98906202A priority patent/EP0972011A4/en
Publication of WO1998035015A1 publication Critical patent/WO1998035015A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Definitions

  • the present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel human cyclin-dependent kinase (CDK) comprising a novel cyclin binding domain signature sequence and lacking several heretofore conserved amino acid residues involved in regulation of the cdk/cyclin complex.
  • CDK human cyclin-dependent kinase
  • the present invention also relates to associated human CDK proteins and human CDK mutant proteins.
  • the cell cycle consists of two major events separated by two central gap phases. DNA synthesis and replication occur during the S phase while mitosis occurs during the M phase. A first gap phase, called Gi, which occurs between the M phase and the S phase, allows for accumulation of enzymes and other compounds necessary to drive DNA synthesis and genome replication. A second gap phase, called G2, occurs between the S phase and the M phase, allowing for controls to check for proper DNA replication prior to committing to cell division. protein kinases (CDKs).
  • CDKs protein kinases
  • CDK1 - CDK6 phosophorylation of threonine 160/161 (Thrl60/161).
  • CDKs contain a cyclin binding site near the amino terminal portion of the protein.
  • the activated CDK/cyclin complex phosphorylates proteins involved in various stages of the cell cycle.
  • the family of cyclin proteins may generally be classified as either Gi cyclins or mitotic cyclins, depending on peak expression levels.
  • a CDK may bind a subset of cyclins.
  • CDK4 is known to bind cyclin Dl or cyclin D3
  • CDK2 is known to bind cyclin A, cyclin Bl, cyclin B2, cyclin B3 and cyclin E.
  • the vertebrate cyclins show homology within a region of approximately 100 amino acids, referred to as the cyclin box. This region is responsible for CDK binding and activity (Kobayashi, et al., 1992, Molec. Biol. Cell. 3: 1279-1294; Lees, et al., 1993, Molec. Cell. Biol., 1993, 13: 1194-1201). It is this region of the cyclin protein which interacts with the cyclin binding domain of a respective CDK protein.
  • CAK CDK- Activating Kinase
  • CDK/cyclin complexes are thought to occur via phosphorylation at threonine 14 (Thrl4) and/or tyrosine 15 (Tyrl ⁇ ) of the CDK subunit.
  • Thrl4 threonine 14
  • Tyrl ⁇ tyrosine 15
  • the Weel kinase has been suggested as either a Thrl4 kinase or as a Thrl4 and Tyrl ⁇ kinase.
  • CDC25 is thought to be a dual kinase targeting both Thrl4 and/or Tyrl ⁇ (Morgan, 1995, Nature 374: 131-134).
  • a nucleic acid molecule expressing a CDK protein would be extremely useful in screening for compounds acting as a modulator of the cell cycle. Such a compound or compounds will be useful in controlling cell growth associated with cancer or immune cell proliferation. Additionally, the recombinant form of protein expressed from such a novel gene would be useful for an in vitro assay to determine specificity toward substrate proteins, inhibitors and cyclin activators. Additionally, an isolated and purified CDK10 cDNA which encodes CDK- 10 or an active mutant thereof will also be useful for the recombinant production of large quantities of respective protein.
  • CDK10 protein The ability to produce large quantities of the protein would be useful for the production of a therapeutic agent comprising the CDK10 protein or a mutant such as the exemplified mutant disclosed herein, A therapeutic agent comprised of CDK10 protein would be useful in the treatment of cell cycle and/or CDK ) related diseases or conditions which are CDK10 responsive.
  • the present invention addresses and meets this need.
  • the present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel human cyclin- dependent kinase.
  • This CDK comprises a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrl ⁇ , and also lacks the T-loop domain containing the conserved Thrl60/161 residue.
  • the present invention relates to biologically active fragments or mutants of a novel isolated nucleic acid molecule which encodes mRNA expressing a novel human cyclin-dependent kinase.
  • Any such biologically active fragment and/or mutant will encode a protein or protein fragment comprising a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), which lacks Thrl4 and/or Tyrl ⁇ as well as a T-loop domain containing the conserved Thrl60/161 residue.
  • Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.
  • the isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
  • DNA deoxyribonucleic acid molecule
  • cDNA complementary DNA
  • synthetic DNA such as a synthesized, single stranded polynucleotide.
  • the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
  • SEQ ID NO:ll and Figure 1 a human DNA fragment which encodes the novel human cyclin-dependent kinase, CDK10.
  • the present invention also relates to a substantially purified novel cyclin-dependent kinase which comprises a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), lacks Thrl4 and Tyrl ⁇ which make up the conserved ATP binding motif of several known CKDs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue.
  • a novel cyclin binding domain signature sequence Pro-Asn-Gln-Ala-Leu-Arg-Glu
  • the present invention also relates to biologically active fragments and/or mutants of a novel cyclin-dependent kinase which comprises a novel cyclin binding domain signature sequence, lacks Thrl4 and/or Tyrl ⁇ which make up the conserved ATP binding motif of known CKDs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.
  • a preferred aspect of the present invention is disclosed in SEQ ID NO:3 and Figure 2, the amino acid sequence of CDK10.
  • the open reading frame of the CDK10 coding region runs from nucleotide 210 to nucleotide 1182 of SEQ ID NO:2.
  • SEQ ID NO:ll Another preferred aspect of the present invention is disclosed in SEQ ID NO:ll, wherein nucleotide ⁇ 88 of the wild-type form (SEQ ID NO: 2) is mutated from “G" to "A".
  • mutant protein (CDK10-D127N), wherein nucleotide ⁇ 88 of SEQ ID NO:ll is mutated from “G” to "A”, as compared to the wild-type form (SEQ ID NO:2), which results in a change of Aspl27 to Asnl27 as compared to the wild-type amino acid sequence (SEQ ID NO:3), disclosed as SEQ ID NO:12.
  • the present invention also relates to methods of expressing the cyclin-dependent kinases disclosed herein, assays employing these cyclin-dependent kinases, cells expressing these cyclin-dependent
  • cyclin-dependent kinases and compounds identified through the use of these cyclin-dependent kinases, including modulators of the cyclin-dependents kinase either through direct contact with the cyclin-dependent kinase, an associated cyclin, or the CKD/cyclin complex.
  • modulators identified in this process are useful as therapeutic agents for controlling cell growth or immune cell proliferation commonly associated with cancer.
  • Figure 2 shows the amino acid sequence (SEQ ID NO:3) of human CDK10.
  • Figure 3 shows the strategy utilized to generate a full- length DNA fragment encoding human CDK10.
  • Figure 4 shows northern blot analysis of human tissue
  • Figure ⁇ shows northern blot analysis of human tissue
  • the present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel cyclin-dependent kinase which comprises a novel human cyclin binding domain (Pro- Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrl ⁇ which make up the conserved ATP binding motif of known CDKs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue.
  • polynucleotide which encodes a novel cyclin-dependent kinase which comprises a novel human cyclin binding domain (Pro- Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l)
  • Thrl4 and/or Tyrl ⁇ which make up the conserved ATP binding motif of known CDKs
  • T-loop domain containing the conserved Thrl60/161 residue.
  • the present invention also relates to biologically active fragments and/or mutants of a novel isolated nucleic acid molecule which encode mRNA expressing a novel human cyclin-dependent kinase.
  • a novel isolated nucleic acid molecule which encode mRNA expressing a novel human cyclin-dependent kinase.
  • Such a protein comprises a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrl ⁇ , and also lack a T-loop domain containing the conserved Thrl60/161 residue.
  • the protein of the present invention includes but is not limited to nucleotide substitutions, deletions, additions, amino terminal truncations and carboxy- terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.
  • FIG. 1 A preferred aspect of the present invention is disclosed in Figure 1 and SEQ ID NO:2, a human cDNA encoding a novel cyclin- dependent kinase, CDK10, disclosed herein as: GAAAAGGCGC AGTGGGGCCC GGAGCTGTCA CCCCTGACTC GACGCAGCTT CCGTTCTCCT GGTGACGTCG CCTACAGGAA CCGCCCCAGT GGTCAGCTGC CGCGCTGTTG CTAGGCAACA GCGTGCGAGC TCAGATCAGC GTGGGGTGGA GGAGAAGTGG AGTTTGGAAG TTCAGGGGCA CAGGGGCACA GGCCCACGAC TGCAGCGGGA TGGACCAGTA CTGCATCCTG GGCCGCATCG GGGAGGGCGC CCACGGCATC GTCTTCAAGG CCAAGCACGT GGAGACTGGC GAGATAGTTG CCCTCAAGAA GGTGGCCCTA AGGCGGTTGG AAGACGGCTT CCCTAACCAG GCCCTGCG
  • the present invention also relates to a substantially purified novel cyclin-dependent kinase which comprises a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu- Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrl ⁇ as well as the T-loop domain containing the conserved Thrl60/161 residue.
  • Any such nucleic acid may be isolated and characterized from a mammalian cell, including but not limited to human, human and rodent.
  • a human form is an especially preferred form, such as the isolated cDNA exemplified herein as set forth in SEQ ID NO:2 and a dominant negative mutant form as set forth in SEQ ID NO: 12.
  • the present invention also relates to biologically active fragments and/or mutants of a novel cyclin-dependent kinase which comprises the novel cyclin binding domain (Pro-Asn-Gln-Ala-Leu- Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrl ⁇ which make up the conserved ATP binding motif of known CDKs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy- terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.
  • Any such nucleic acid may be isolated and characterized from a mammalian cell, including but not limited to human, human and rodent, with a human form being an especially preferred form.
  • a preferred aspect of the present invention is disclosed in SEQ ID NO:3 and Figure 2, the amino acid sequence of CDK10.
  • the open reading frame of the CDK10 coding region runs from nucleotide 210 to nucleotide 1182 of SEQ ID NO:2.
  • the amino acid sequence of the novel cyclin-dependent kinase, CDK10 is disclosed herein as:
  • SEQ ID NO:ll Another preferred aspect of the present invention is disclosed in SEQ ID NO:ll, wherein nucleotide ⁇ 88 of the wild-type form (SEQ ID NO: 2) is mutated from “G" to "A".
  • mutant protein (CDK10-D127N), wherein nucleotide ⁇ 88 of SEQ ID NO:ll is mutated from “G” to "A”, as compared to the wild-type form (SEQ ID NO:2), which results in a change of Aspl27 to Asnl27 as compared to the wild-type amino acid sequence (SEQ ID NO:3), disclosed as SEQ ID NO:12.
  • the present invention also relates to methods of expressing the cyclin-dependent kinases disclosed herein, assays employing these cyclin-dependent kinases, cells expressing these cyclin-dependent kinases, and compounds identified through the use of these cyclin- dependent kinases, including modulators of the cyclin-dependents kinase either through direct contact with the cyclin-dependent kinase, an associated cyclin, or the CKD/cyclin complex. Such modulators identified in this process are useful as therapeutic agents for controlling cell growth or immune cell proliferation associated with human cancers. Additionally, an isolated and purified CDK10 cDNA which encodes CDK-10 or an active mutant thereof will also be useful for the recombinant production of large quantities of respective protein.
  • a therapeutic agent comprised of CDK10 protein would be useful in the treatment of cell cycle and/or CDK10 related diseases or conditions which are CDKIO responsive or possibly a therapeutic agent comprised of a mutant, including but not limited to CDK10-D127N, which may be useful in the treatment of cell cycle diseases or conditions which are responsive to the regulatory effects of the mutant kinase.
  • the isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
  • DNA deoxyribonucleic acid molecule
  • cDNA complementary DNA
  • synthetic DNA such as a synthesized, single stranded polynucleotide.
  • the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
  • this invention is also directed to those DNA sequences which contain alternative codons which code for the eventual translation of the identical amino acid.
  • a sequence bearing one or more replaced codons will be defined as a degenerate variation.
  • mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide. Therefore, this invention is also directed to those DNA sequences which express RNA comprising alternative codons which code for the eventual translation of the identical amino acid, as shown below:
  • DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally occurring peptide.
  • Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a receptor for a ligand.
  • DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally- occurring peptide.
  • Methods of altering the DNA sequences include, but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a receptor for a ligand.
  • a "biologically active equivalent” or “functional derivative” of a wild type CDK possesses a biological activity that is substantially similar to the biological activity of the wild type CDKIO protein.
  • the term “functional derivative” is intended to include the “fragments,” “mutants,” “variants,” “degenerate variants,” “analogs” and “homologues” or to “chemical derivatives” of the wild type CDKIO protein.
  • fragment is meant to refer to any polypeptide subset of wild type CDKIO.
  • mutant is meant to refer to a molecule that may be substantially similar to the wild type form but possesses distinguishing biological characteristics.
  • Such altered characteristics include but are in no way limited to altered enzymatic activity, altered cyclin binding altered substrate binding, altered substrate affinity and altered sensitivity to chemical compounds affecting biological activity.
  • An exemplified mutant is CDK10-D127N, wherein a single base mutation at nucleotide ⁇ 88 of SEQ ID NO:2 results in a single amino acid substitution at residue 127, from aspartic acid to asparagine. This mutation alters kinase activity of CDK10-D127N as compared to the wild type CDKIO protein.
  • variant is meant to refer to a molecule substantially similar in structure and function to either the entire wild type protein or to a fragment thereof.
  • a molecule is "substantially similar" to a wild type CDKlO-like protein if both molecules have substantially similar structures or if both molecules possess similar biological activity. Therefore, if the two molecules possess substantially similar activity, they are considered to be variants even if the structure of one of the molecules is not found in the other or even if the two amino acid sequences are not identical.
  • analog refers to a molecule substantially similar in function to either the entire wild type CDKlO-like protein or to a fragment thereof.
  • Substantial homology or “substantial similarity”, when referring to nucleic acids means that the segments or their complementary strands, when optimally aligned and compared, are identical with appropriate nucleotide insertions or deletions, in at least 7 ⁇ % of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize to a strand or its complement.
  • nucleic acids claimed herein may be present in whole cells or in cell lysates or in a partially purified or substantially purified form. A nucleic acid is considered substantially purified when it is purified away from environmental contaminants. Thus, a nucleic acid sequence isolated from cells is considered to be substantially purified when purified from cellular components by standard methods while a chemically synthesized nucleic acid sequence is considered to be substantially purified when purified from its chemical precursors.
  • any of a variety of procedures may be used to clone CDKIO. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, Proc. Natl. Acad. Sci.85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of CDKIO cDNA.
  • These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the CDKIO cDNA following the construction of an CDKlO-containing cDNA library in an appropriate expression vector system; (3) screening a CDK10- containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the CDKIO protein; (4) screening a CDKlO-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the CDK10 protein.
  • EST expressed sequence tag
  • This partial cDNA is obtained by the specific PCR amplification of CDK10 DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other CDK kinases which are related to the CDK10 protein; ( ⁇ ) screening an CDKlO-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the CDK10 protein.
  • This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of CDK10 cDNA identified as an EST as described above; or (6) designing ⁇ ' and 3' gene specific oligonucleotides using SEQ ID NO:2 as a template so that either the full length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and or genomic libraries in order to - isolate a full length version of the nucleotide sequence encoding CDKIO.
  • CDKlO-encoding DNA or a CDKIO homologue Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines other than human cells or tissue such as murine cells, rodent cells or any other such vertebrate host which may contain a CDKlO-encoding DNA. Additionally a CDKIO gene may be isolated by oligonucleotide- or polynucleotide- based hybridization screening of a vertebrate genomic library, including but not limited to a human genomic library, a murine genomic library and a rodent genomic library, as well as concomitant human genomic DNA libraries.
  • cDNA libraries may be prepared from cells or cell lines which have CDKIO activity.
  • the selection of cells or cell lines for use in preparing a cDNA library to isolate a CDKIO cDNA may be done by first measuring cell associated CDKIO activity using any known assay for CDK activity.
  • cDNA libraries can be performed by standard techniques well known in the art.
  • Well known cDNA library construction techniques can be found for example, in Sambrook, et al., 1989, Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
  • Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene. It is also readily apparent to those skilled in the art that DNA encoding CDKIO may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in Sambrook, et al., supra.
  • the amino acid sequence or DNA sequence of CDKIO or a homologous protein may be necessary.
  • the CDKIO or a homologous protein may be purified and partial amino acid sequence determined by automated sequenators. It is not necessary to determine the entire amino acid sequence, but the linear sequence of two regions of 6 to 8 amino acids can be determined for the PCR amplification of a partial CDKIO DNA fragment. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized.
  • the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the CDKIO sequence but others in the set will be capable of hybridizing to CDKIO DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still sufficiently hybridize to the CDKIO DNA to permit identification and isolation of CDKIO encoding DNA. Alternatively, the nucleotide sequence of a region of an expressed sequence may be identified by searching one or more available genomic databases.
  • Gene-specific primers may be used to perform PCR amplification of a cDNA of interest from either a cDNA library or a population of cDNAs.
  • the appropriate nucleotide sequence for use in a PCR-based method may be obtained from SEQ ID NO:2, either for the purpose of isolating overlapping ⁇ ' and 3' RACE products for generation of a full-length sequence coding for CDKIO, or to isolate a portion of the nucleotide sequence coding for CDKIO for use as a probe to screen one or more cDNA- or genomic-based libraries to isolate a full-length sequence encoding CDKIO or CDKlO-like proteins.
  • the RACE PCR technique the RACE PCR technique
  • PCR amplification was performed using the ElongaseTM. Thermal cycling was completed and a portion of this first PCR reaction was added to a second PCR reaction as DNA template. This PCR reaction also differed from the first PCR reaction in that the nested gene specific primer PK22L161
  • a DNA fragment 3' to and overlapping the 600 bp 5' fragment was identified by searching public nucleic acid and protein databases.
  • This 3' fragment is an approximately 1.8 Kb cDNA insert available as a Notl-Hindlll fragment in a typical phagemid vector.
  • This cDNA clone is readily identified by Genbank Accession No. H17727, Image Clone ID No. 60484, Washington University Clone ID No. ym40a06, and GBD Clone ID No. 423294.
  • This cDNA was isolated from a library constructed from human infant brain mRNA. This construct is available from Research Genetics, Inc., 2130 Memorial Parkway SW, Hunstville, AL 3 ⁇ 801 (http://www. resgen.com).
  • CDKIO coding region was assembled in pLITMUS28 (New England Biolabs) as an expression cassette with a BamHI site appended just ⁇ ' to the ATG translational start codon.
  • a BamHI-Xbal fragment bearing CDK10 was recloned into pcDNA3.1 expression vector (Invitrogen) and a BamHI-Ncol fragment bearing CDK10 was recloned into pBlueBacHis2 baculovirus expression vector (Invitrogen).
  • a similar construct was generated which contains dominant-negative single base pair mutation of CDKIO. This mutant was generated from pLITMUS28::CDK10 using the Stratagene "Quik Change" kit and primers 22U-D127N
  • mutant constructions were subcloned into pcDNA3.1 (as a BamHI-Xbal fragment) and pBlueBacHis2 (as a BamHI- Ncol fragment), respectively.
  • the sequence for the ⁇ ' upstream sequences, coding region and 3' untranslated sequences for the human full-length cDNA encoding CDKIO is shown in SEQ ID NO:2.
  • the deduced amino acid sequence of CDKIO from the cloned cDNA is shown in SEQ ID NO:3. Inspection of the determined cDNA sequence reveals the presence of a single open reading frame that encodes a 32 ⁇ amino acid protein.
  • the open reading frame of the CDKIO coding region runs from nucleotide 210 to nucleotide 1182 of SEQ ID NO:2.
  • nucleotide sequence which encodes a preferred mutant form is disclosed as SEQ ID NO:ll.
  • a variety of mammalian expression vectors may be used to express recombinant CDKIO in mammalian cells.
  • Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their mRNAs in an appropriate host.
  • Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, blue green algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria- animal cells.
  • An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters.
  • a promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis.
  • a strong promoter is one which causes mRNAs to be initiated at high frequency.
  • Expression vectors may include, but are not limited to, cloning
  • I* vectors modified cloning vectors, specifically designed plasmids or viruses.
  • mammalian expression vectors which may be suitable for recombinant CDKIO expression, include but are not limited to, pcDNA3.1 (Invitrogen), pBlueBacHis2 (Invitrogen), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Bioloabs), pcDNAI, pcDNAIamp (Invitrogen), pcDNA3 (Invitrogen), pMClneo (Stratagene), pXTl (Stratagene), pSG ⁇ (Stratagene), EBO-pSV2-neo (ATCC 37 ⁇ 93) pBPV- 1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC
  • bacterial expression vectors may be used to express recombinant CDKIO in bacterial cells.
  • Commercially available bacterial expression vectors which may be suitable for recombinant CDKIO expression include, but are not limited to pCR2.1 (Invitrogen), pETlla (Novagen), lambda gtll (Invitrogen), pcDNAII (Invitrogen), pKK223-3 (Pharmacia).
  • fungal cell expression vectors may be used to express recombinant CDK10 in fungal cells.
  • Commercially available fungal cell expression vectors which may be suitable for recombinant CDK10 expression include but are not limited to pYES2 (Invitrogen), Pichia expression vector (Invitrogen).
  • insect cell expression vectors may be used to express recombinant receptor in insect cells.
  • Commercially available insect cell expression vectors which may be suitable for recombinant expression of CDK10 include but are not limited to pBlueBacIII and pBlueBacHis2 (Invitrogen).
  • the expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, lipofection, protoplast fusion, and electroporation.
  • the expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce CDK10 protein. Identification of CDK10 expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-CDKlO antibodies.
  • CDKIO DNA may also be performed using in vitro produced synthetic mRNA or native mRNA.
  • Synthetic mRNA or mRNA isolated from CDKIO producing cells can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.
  • An expression vector containing DNA encoding a CDKlO- like protein may be used for expression of CDKIO in a recombinant host cell.
  • Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as E. coli, fungal cells such as yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to Drosophila and silkworm derived cell lines.
  • L cells L-M(TK") ATCC CCL 1.3
  • L cells L-M ATCC CCL 1.2
  • Saos-2 ATCC HTB-8 ⁇
  • 293 ATCC CRL l ⁇ 73
  • Raji ATCC CCL 86
  • CV-1 ATCC CCL 70
  • COS-1 ATCC CRL 16 ⁇ 0
  • COS-7 ATCC CRL 16 ⁇ l
  • CHO-K1 ATCC CCL 61
  • 3T3 ATCC CCL 92
  • NIH/3T3 ATCC CRL 16 ⁇ 8
  • HeLa ATCC CCL 2
  • C127I ATCC CRL 1616
  • BS-C-1 ATCC CCL 26
  • MRC- ⁇ ATCC CCL 171
  • the expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation.
  • the expression vector-containing cells are individually analyzed to determine whether they produce CDKIO protein. Identification of CDKIO expressing cells may be done by several means, including but not limited to immunological reactivity with anti-CDKlO antibodies, and the presence of host cell-associated CDK10 activity.
  • the cloned CDK10 cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector (such as pcDNA3.1, pCR2.1, pBlueBacHis2 and pLITMUS28) containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant CDK10.
  • an expression vector such as pcDNA3.1, pCR2.1, pBlueBacHis2 and pLITMUS28
  • Techniques for such manipulations can be found described in Sambrook, et al., supra , are discussed at length in the Example section and are well known and easily available to the artisan of ordinary skill in the art.
  • CDKIO DNA may also be performed using in vitro produced synthetic mRNA.
  • Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.
  • CDKIO cDNA molecules including but not limited to the following can be constructed: the full-length open reading frame of the CDKIO cDNA and various constructs containing portions of the cDNA encoding only specific domains of the protein or rearranged domains of the protein.
  • CDKIO activity and levels of protein expression can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells.
  • this CDKIO cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells.
  • levels of CDKIO protein in host cells is quantified by a variety of techniques including, but not limited to, immunoaffinity and/or ligand affinity techniques.
  • CDKlO-specific affinity beads or CDKlO-specific antibodies are used to isolate 3 ⁇ S-methionine labeled or unlabelled CDKIO protein. Labeled CDKIO protein is analyzed by SDS- PAGE. Unlabelled CDKIO protein is detected by Western blotting, ELISA or RIA assays employing CDKIO specific antibodies.
  • CDKIO protein may be recovered to provide CDKIO in active form.
  • CDKIO purification procedures are available and suitable for use.
  • Recombinant CDKIO may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography.
  • recombinant CDKIO can be separated from other cellular proteins by use of an immuno- affinity column made with monoclonal or polyclonal antibodies specific for full length CDKIO, or polypeptide fragments of CDKIO.
  • polyclonal or monoclonal antibodies may be raised against a synthetic peptide (usually from about 9 to about 2 ⁇ amino acids in length) from a portion of the protein as disclosed in SEQ ID NO:3.
  • Monospecific antibodies to CDKIO are purified from mammalian antisera containing antibodies reactive against CDKIO or are prepared as monoclonal antibodies reactive with CDKIO using the technique of Kohler and Milstein (197 ⁇ , Nature 2 ⁇ 6: 49 ⁇ -497).
  • Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for CDKIO.
  • Homogenous binding refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the CDKIO, as described above.
  • CDKIO specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of CDKIO or CDKIO synthetic peptide either with or without an immune adjuvant.
  • Preimmune serum is collected prior to the first immunization.
  • Each animal receives between about 0.1 ⁇ g and about 1000 ⁇ g of CDK10 associated with an acceptable immune adjuvant.
  • acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA.
  • the initial immunization consists of the CDK10 protein or CDK10 synthetic peptide in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both.
  • SC subcutaneously
  • IP intraperitoneally
  • Each animal is bled at regular intervals, preferably weekly, to determine antibody titer.
  • the animals may or may not receive booster injections following the initial immunizaiton. Those animals receiving booster injections are generally given an equal amount of CDK10 in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20°C.
  • Monoclonal antibodies (mAb) reactive with CDKIO are prepared by immunizing inbred mice, preferably Balb/c, with CDKIO.
  • the mice are immunized by the IP or SC route with about 1 ⁇ g to about 100 ⁇ g, preferably about 10 ⁇ g, of CDKIO in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred.
  • the mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks.
  • Immunized mice are given one or more booster immunizations of about 1 to about 100 ⁇ g of CDK10 in a buffer solution such as phosphate buffered saline by the intravenous (IV) route.
  • Lymphocytes from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art.
  • Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas.
  • Fusion partners may include, but are not limited to: mouse myelomas P3/NSl/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred.
  • the antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%.
  • Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art.
  • DMEM Dulbecco's Modified Eagles Medium
  • Supernatant fluids are collected form growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using CDK10 as the antigen.
  • SPIRA solid phase immunoradioassay
  • the culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb.
  • Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, 1973, Soft Agar Techniques, in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press.
  • Monoclonal antibodies are produced in vivo by injection of pristine primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x 10" to about 6 x 10" hybridoma cells about 4 days after priming.
  • X and the monoclonal antibodies are purified by techniques known in the art.
  • In vitro production of anti-CDKlO mAb is carried out by growing the hydridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb.
  • the mAb are purified by techniques known in the art.
  • Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of CDKIO in body fluids or tissue and cell extracts.
  • CDKIO antibody affinity columns are made by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support.
  • the antibodies are then coupled to the gel via amide bonds with the spacer arm.
  • the remaining activated esters are then quenched with 1M ethanolamine HC1 (pH 8).
  • the column is washed with water followed by 0.23 M glycine HCl (pH 2.6) to remove any non-conjugated antibody or extraneous protein.
  • the column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing CDKIO or CDKIO fragments are slowly passed through the column.
  • the column is then washed with phosphate buffered saline until the optical density (A280) falls to background, then the protein is eluted with 0.23 M glycine-HCl (pH 2.6).
  • the purified CDK10 protein is then dialyzed against phosphate buffered saline.
  • the novel CDK10 of the present invention is suitable for use in an assay procedure for the identification of compounds which modulate CDK10 activity.
  • Modulating CDK10 activity, as described herein includes the inhibition or activation of the protein and also includes directly or indirectly affecting the cell cycle regulatory properties associated with CDK10 activity.
  • Compounds which modulate CDKIO activity include agonists, antagonists, inhibitors, activators, and compounds which directly or indirectly affect regulation of the CDKIO activity and/or the CDKlO/cyclin association.
  • the CDKIO protein kinase of the present invention may be obtained from both native and recombinant sources for use in an assay procedure to identify CDKIO modulators.
  • an assay procedure to identify CDKIO modulators will contain the CDKlO-protein of the present invention, native cyclin protein which will form a CDKlO/cyclin complex, and a test compound or sample which contains a putative CDKIO modulator.
  • the test compounds or samples may be tested directly on, for example, purified CDKIO protein whether native or recombinant, subcellular fractions of CDKlO-producing cells whether native or recombinant, and/or whole cells expressing the CDKIO whether native or recombinant.
  • the test compound or sample may be added to the CDKIO in the presence or absence of a known CDKIO modulator.
  • the modulating activity of the test compound or sample may be determined by, for example, analyzing the ability of the test compound or sample to bind to CDKIO protein, activate the protein, inhibit CDKIO activity, inhibit or enhance the binding of other compounds to the CDKIO protein, modifying receptor regulation, or modifying an intracellular activity.
  • modulators of CDKIO activity are useful in treating disease states involving the cell cycle will be useful in controlling cell growth associated with cancer or immune cell proliferation.
  • Other compounds may be useful for stimulating or inhibiting activity of the enzyme. These compounds could be of use in the treatment of diseases in which activation or inactivation of the CDKIO protein results in either cellular proliferation, cell death, nonproliferation, induction of cellular neoplastic transformations or metastatic tumor growth and hence could be used in the prevention and/or treatment of various cancers.
  • the present invention is also directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding a CDK protein of the present invention or which modulates the function of a such a CDK protein.
  • Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules.
  • Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding the CDK protein, or the function of a CDK protein.
  • Compounds that modulate the expression of DNA or RNA encoding the CDK protein or the biological function thereof may be detected by a variety of assays.
  • the assay may be a simple "yes/no" assay to determine whether there is a change in expression or function.
  • the DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of CDKIO DNA, RNA or protein.
  • the recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of CDKIO.
  • a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container.
  • the carrier would further comprise reagents such as recombinant CDKIO protein or anti-CDKlO antibodies suitable for detecting CDKIO.
  • the carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.
  • compositions comprising modulators of CDKIO may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences.
  • a pharmaceutically acceptable composition suitable for effective administration such compositions will contain an effective amount of the protein, DNA, RNA, or modified CDKIO.
  • Therapeutic or diagnostic compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders. The effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
  • compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.
  • chemical derivative describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half- life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.
  • the present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.
  • the compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration.
  • the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the active agents can be administered concurrently, or they each can be administered at separately staggered times.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites.
  • CDKIO This involves a consideration of the distribution, equilibrium, and elimination of a drug Isolated and purified CDKIO is also be useful for the recombinant production of large quantities of CDKIO protein.
  • the ability to produce large quantities of the protein would be useful for the production of a therapeutic agent comprising the CDKIO protein.
  • a therapeutic agent comprised of CDKIO protein would be useful in the treatment of cell cycle and/or CDKIO related diseases or conditions which are CDKIO responsive.
  • This new cDNA fragment encodes a novel cyclin-dependent kinase which comprises a novel cyclin binding domain signature sequence, lacks Thrl4 and/or Tyrl ⁇ within the conserved ATP binding motif of known CDKs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue.
  • This cDNA was isolated from a library constructed from human infant brain mRNA. This construct is available from Research Genetics, Inc., 2130 Memorial Parkway SW, Hunstville, AL 3 ⁇ 801 (http://www. resgen.com). The ⁇ ' portion of the gene was isolated by performing ⁇ ' RACE (Frohman, et al., 1988, Proc. Natl. Acad. Sci.85 8998-9002) using MarathonTM-ready human placenta cDNA available from Clontech (Protocol #PTll ⁇ 6-l, Catalog #K1802-1).
  • Adapter-ligated double stranded cDNA generated from human placenta mRNA was used as a template for PCR amplification using a gene specific primer PK22L234 (5'-TGATGCAGCCCACAGACCTG-3'; SEQ ID NO: 4) and an adapter primer API (5'-CCATCCTAATACGACTCACTATAGGGC-3' SEQ ID NO: ⁇ ).
  • PCR amplification was performed using the ElongaseTM long- PCR enzyme mix (stored in 20mM Tris-HCl (pH 8.0 at 2 ⁇ °C), O.lmM EDTA, ImM DTT, stabilizers and ⁇ 0%(v/v) glycerol) and PCR reaction buffer obtained from Gibco-BRL.
  • the buffer comprised 300mM Tris-S ⁇ 4 (pH 9.1 at 2 ⁇ °C), 90mM (NH4) 2 S04 and l. ⁇ mM MgS04- Two microliters of Marathon placenta cDNA template and 10 pmoles each of PK22L234 and API were added to the reaction mix and brought to a total volume of 20ml with sterile water. Thermal cycling was (1) 94°C/30sec, 68°C/6min for ⁇ cycles; (2) 94°C/30sec, 64°C/30sec, 68°C/4min for ⁇ cycles; and, (3) 1 94°C/30sec, 62°C/30sec and 68°C/4min for 30 cycles.
  • This PCR reaction also differed from the first PCR reaction in that nested primers PK22L161 ( ⁇ '-GCCGTCTGGGGAAAAGA-3'; SEQ ID NO:6) and AP2
  • the MarathonTM -ready human placenta cDNA available from Clontech is enhanced by ligation of a double-stranded, ⁇ ' overhang adapter to the double stranded cDNA template.
  • the 3' end of the adapter is blocked by an amine group to prevent extension during PCR amplification. It is within the non-extended 3' region that the API oligo will hybridize. Therefore, API does not hybridize and extend any of the original cDNA template molecules, instead beginning extension and amplification in the second round of PCR.
  • the 3' portion of a DNA fragment which encodes CDK10 is contained within a DNA plasmid vector, pH17727.
  • This insert contains a ⁇ ' Xhol site unique to the insert and a Ncol site in the 3' unstranslated region unique to the insert.
  • This Xhol-Ncol fragment was isolated and subcloned into Xhol-Ncol digested pLITMUS28 plasmid DNA (New England Biolabs), resulting in pLITMUS28:H17727.
  • the 600 bp PCR fragments obtained from ⁇ ' RACE were cloned into pCR2.1 (Invitrogen) using the Invitrogen TA-cloning kit as described by the manufacturer.
  • a Pmll restriction site is located at approximately the midpoint of the 600 bp PCR product. The Pmll site was used to construct a wild type form of the 600 bp ⁇ ' fragment from 2 independent ⁇ ' RACE PCR clones, pPK22bo4 and pPK22do4.
  • a BamHI-Xbal fragment from pLITMUS28:CDK10 comprising the CKD10 coding region was subcloned into the mammalian expression vector, pcDNA3.1 (Invitrogen), which was previously digested with BamHI and Xbal.
  • the resulting construct, pcDNA3.1:CDK10 contains a portion of the CMV promoter and a T7 primer site upstream of the CDKIO ATG translational start codon as well as the BGH polyA region downstream of the translational termination codon.
  • other components to allow growth in E. coli and mammalian cells are present in this vector.
  • a BamHI-Ncol fragment from pLITMUS28: CDKIO containing the CKDIO coding region was cloned into the baculovirus expression vector, pBlueBacHis2 (Invitrogen), which was previously digested with BamHI and Ncol.
  • the resulting construct, pBBH:CDK10 may be used to express recombinant CDKIO from insect cells by
  • the pLITMUS:CDK10 construct (see Example 2) was mutated to generate a "dominant-negative" single base pair mutation. This mutation was generated from pLITMUS28:CDK10 using the Stratagene "Quik Change” kit and primers 22U-D127N:
  • the dominant-negative mutation changes the codon GAC (at nucleotides ⁇ 88- ⁇ 90 of SEQ ID NO:2) to AAC (at nucleotides ⁇ 88- ⁇ 90 of SEQ ID NO: 11), thus deletion essential amino acid Aspl27 to Asnl27 (see SEQ ID NO:12), which inactivates kinase activity (see Example 7 and van den Heuvel & Harlow, 1993, Science 262:20 ⁇ 0-20 ⁇ 4).
  • a CDK10-D127N construction was subcloned into pcDNA3.1 (as a BamHI-Xbal fragment), resulting in pcDNA3.1:CDK10-dl27N.
  • a CDK10-D127N construction was also subcloned into pBlueBacHis2 (as a BamHI-Ncol fragment), resulting in P BBH:CDK10-dl27N.
  • Human multiple tissue Northern Blot #7760-1, Human Brain Northern Blot II #7755-1, Human Brain Northern Blot III #7750-1, and "Human multiple tissue Northern Dot Blot were purchased from Clontech. The probe was made by PCR amplifying the Notl-Hindlll insert from pH17727 using the "Universal"
  • Figure 4 and Figure ⁇ show Northern data indicating the presence of CDKIO transcripts in a variety of adult human tissue ( Figure 4) as well as in specific regions of the adult and fetal human brain ( Figure ⁇ ). This data shows increased expression levels in the testis as well as in pituitary and adrenal glands. Expression in various regions of the brain was relatively constant, with increased expression seen in the frontal and temporal lobes and the cerebral cortex.
  • Human osteosarcoma cell line Saos2 (ATCC HBT-8 ⁇ ) was grown in DMEM high glucose medium + glutamine +10% fetal calf serum (in concentrations as recommended by Gibco-BRL). Two replicates of the experiment were performed sequentially. Cells were split 1:6 into 10 cm culture dishes two days prior to transfection. Transfection was performed using the CaP04 method according to Chen and Okayama (1987, Mol. and Cell. Biol. 7:-274 ⁇ -27 ⁇ 2). Ten ug of each plasmid DNA (pcDNA3.1, pcDNA3:CDK10, pcDNA3:CDK10-D127N) was transfected into ⁇ 60% confluent cells in each 10 cm dish.
  • HeLa cervical carcinoma cells were treated for 48 hours with a control adenovirus deleted for the El and E3 genes or the same adenovirus which comprised the construct encoding CDK10-D127N.
  • Western blots were performed with a rabbit antibody raised to the C-terminal 25 amino acids of the CDKIO protein (amino acid 301 - amino acid 325 of SEQ ID NO: 3).
  • the cell line transfected with Ad/CDKIO- D127N expressed CDK10-D127N at a ⁇ O-fold higher level than endogenous, wild type CDKIO.
  • the two infected cell populations were subjected to mRNA isolations and probes were prepared for gene expression DNA chip studies essentially as described by Lockhart, et al. (1996, Nature Biotechnology 14:1675-1680).
  • Table 2 the genes which were suppressed at the mRNA level by CDK10-D127N are summarized in Table 2.
  • a therapeutic agent comprising the CDKIO protein would be useful in the treatment of cell cycle and/or CDKIO related diseases or conditions which are CDKIO responsive as well as showing a potential use for a dominant-negative mutant such as CDK10-D127N, which may be useful in the treatment of cell cycle diseases or conditions which are responsive to the mtuant proteins ability to regulate a phase or phases of the cell cycle.
  • CTTCACCCTC CAAGGCCTCC CCATGGCCAC AGTGGGCCCA CACCACACCC TGCCCCTTAG 1320
  • CTTCACCCTC CAAGGCCTCC CCATGGCCAC AGTGGGCCCA CACCACACCC TGCCCCTTAG 1320

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

An isolated nucleic acid molecule is disclosed which encodes a novel human cyclin-dependent kinase (CDK) which comprises a novel cyclin binding domain signature sequence and lacks several heretofore conserved amino acid residues involved in regulation of the cdk/cyclin complex. Associated proteins and biologically active mutant forms are also disclosed.

Description

TITLE OF THE INVENTION CYCLIN-DEPENDENT PROTEIN KINASE
CROSS-REFERENCE TO RELATED APPLICATIONS
Provisional Application U.S. Serial Number 60/037,855 filed February 7, 1997.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH Not applicable.
REFERENCE TO MICROFICHE APPENDLX Not applicable.
FIELD OF THE INVENTION
The present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel human cyclin- dependent kinase (CDK) comprising a novel cyclin binding domain signature sequence and lacking several heretofore conserved amino acid residues involved in regulation of the cdk/cyclin complex. The present invention also relates to associated human CDK proteins and human CDK mutant proteins.
BACKGROUND OF THE INVENTION
Cell growth and division in eukaryotic organisms is mediated through the cell cycle. The cell cycle consists of two major events separated by two central gap phases. DNA synthesis and replication occur during the S phase while mitosis occurs during the M phase. A first gap phase, called Gi, which occurs between the M phase and the S phase, allows for accumulation of enzymes and other compounds necessary to drive DNA synthesis and genome replication. A second gap phase, called G2, occurs between the S phase and the M phase, allowing for controls to check for proper DNA replication prior to committing to cell division. protein kinases (CDKs). Activation of a CDK requires binding to a cyclin regulatory subunit, and in the case of CDK1 - CDK6, phosophorylation of threonine 160/161 (Thrl60/161). These CDKs contain a cyclin binding site near the amino terminal portion of the protein. The activated CDK/cyclin complex phosphorylates proteins involved in various stages of the cell cycle.
The family of cyclin proteins may generally be classified as either Gi cyclins or mitotic cyclins, depending on peak expression levels.
A CDK may bind a subset of cyclins. For example, CDK4 is known to bind cyclin Dl or cyclin D3 whereas CDK2 is known to bind cyclin A, cyclin Bl, cyclin B2, cyclin B3 and cyclin E. The vertebrate cyclins show homology within a region of approximately 100 amino acids, referred to as the cyclin box. This region is responsible for CDK binding and activity (Kobayashi, et al., 1992, Molec. Biol. Cell. 3: 1279-1294; Lees, et al., 1993, Molec. Cell. Biol., 1993, 13: 1194-1201). It is this region of the cyclin protein which interacts with the cyclin binding domain of a respective CDK protein.
Complete activation of a known CDK/cyclin complex requires phosphorlyation by a CDK- Activating Kinase (CAK). The vertebrate CAK has been identified as a CDK/cyclin complex, more specifically CDK7/cyclinH (Fisher and Morgan, 1994, Cell 78: 713-724). The CAK enzyme comprises a threonine 170 residue (in human CDK7) which has been shown to be required for optimal activity (Poon, et al., 1994, J. Cell Sci. 107: 2789-2799; Fisher and Morgan, 1994, Cell 78: 713- 724).
Inhibition of CDK/cyclin complexes are thought to occur via phosphorylation at threonine 14 (Thrl4) and/or tyrosine 15 (Tyrlδ) of the CDK subunit. The Weel kinase has been suggested as either a Thrl4 kinase or as a Thrl4 and Tyrlδ kinase. Additionally, CDC25 is thought to be a dual kinase targeting both Thrl4 and/or Tyrlδ (Morgan, 1995, Nature 374: 131-134).
It would be advantageous to identify a gene encoding an additional CDK protein. A nucleic acid molecule expressing a CDK protein would be extremely useful in screening for compounds acting as a modulator of the cell cycle. Such a compound or compounds will be useful in controlling cell growth associated with cancer or immune cell proliferation. Additionally, the recombinant form of protein expressed from such a novel gene would be useful for an in vitro assay to determine specificity toward substrate proteins, inhibitors and cyclin activators. Additionally, an isolated and purified CDK10 cDNA which encodes CDK- 10 or an active mutant thereof will also be useful for the recombinant production of large quantities of respective protein. The ability to produce large quantities of the protein would be useful for the production of a therapeutic agent comprising the CDK10 protein or a mutant such as the exemplified mutant disclosed herein, A therapeutic agent comprised of CDK10 protein would be useful in the treatment of cell cycle and/or CDK ) related diseases or conditions which are CDK10 responsive. The present invention addresses and meets this need.
SUMMARY OF THE INVENTION
The present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel human cyclin- dependent kinase. This CDK comprises a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrlδ, and also lacks the T-loop domain containing the conserved Thrl60/161 residue. The present invention relates to biologically active fragments or mutants of a novel isolated nucleic acid molecule which encodes mRNA expressing a novel human cyclin-dependent kinase. Any such biologically active fragment and/or mutant will encode a protein or protein fragment comprising a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), which lacks Thrl4 and/or Tyrlδ as well as a T-loop domain containing the conserved Thrl60/161 residue. Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.
The isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
A preferred aspect of the present invention is disclosed in SEQ ID NO:ll and Figure 1, a human DNA fragment which encodes the novel human cyclin-dependent kinase, CDK10.
The present invention also relates to a substantially purified novel cyclin-dependent kinase which comprises a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), lacks Thrl4 and Tyrlδ which make up the conserved ATP binding motif of several known CKDs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue.
The present invention also relates to biologically active fragments and/or mutants of a novel cyclin-dependent kinase which comprises a novel cyclin binding domain signature sequence, lacks Thrl4 and/or Tyrlδ which make up the conserved ATP binding motif of known CKDs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.
A preferred aspect of the present invention is disclosed in SEQ ID NO:3 and Figure 2, the amino acid sequence of CDK10. The open reading frame of the CDK10 coding region runs from nucleotide 210 to nucleotide 1182 of SEQ ID NO:2.
Another preferred aspect of the present invention is disclosed in SEQ ID NO:ll, wherein nucleotide δ88 of the wild-type form (SEQ ID NO: 2) is mutated from "G" to "A".
Another preferred aspect of the present invention is the mutant protein, (CDK10-D127N), wherein nucleotide δ88 of SEQ ID NO:ll is mutated from "G" to "A", as compared to the wild-type form (SEQ ID NO:2), which results in a change of Aspl27 to Asnl27 as compared to the wild-type amino acid sequence (SEQ ID NO:3), disclosed as SEQ ID NO:12. The present invention also relates to methods of expressing the cyclin-dependent kinases disclosed herein, assays employing these cyclin-dependent kinases, cells expressing these cyclin-dependent
1 kinases, and compounds identified through the use of these cyclin- dependent kinases, including modulators of the cyclin-dependents kinase either through direct contact with the cyclin-dependent kinase, an associated cyclin, or the CKD/cyclin complex. Such modulators identified in this process are useful as therapeutic agents for controlling cell growth or immune cell proliferation commonly associated with cancer.
DETAILED DESCRIPTION OF THE DRAWINGS Figure 1 shows the nucleotide sequence (SEQ ID NO:2) which comprises the full length cDNA encoding human CDK10.
Figure 2 shows the amino acid sequence (SEQ ID NO:3) of human CDK10.
Figure 3 shows the strategy utilized to generate a full- length DNA fragment encoding human CDK10.
Figure 4 shows northern blot analysis of human tissue
32 mRNA hybridized to a P-labeled probe from the 3' region of the
DNA fragment encoding human CDK10.
Figure δ shows northern blot analysis of human tissue
3 322 mRNA hybri ddiizzeedd ttoo aa PP--llaabbeelleedd pprroobbee from the 3' region of the
DNA fragment encoding human CDK10.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel cyclin-dependent kinase which comprises a novel human cyclin binding domain (Pro- Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrlδ which make up the conserved ATP binding motif of known CDKs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue.
The present invention also relates to biologically active fragments and/or mutants of a novel isolated nucleic acid molecule which encode mRNA expressing a novel human cyclin-dependent kinase. Such a protein comprises a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu-Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrlδ, and also lack a T-loop domain containing the conserved Thrl60/161 residue. The protein of the present invention includes but is not limited to nucleotide substitutions, deletions, additions, amino terminal truncations and carboxy- terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.
A preferred aspect of the present invention is disclosed in Figure 1 and SEQ ID NO:2, a human cDNA encoding a novel cyclin- dependent kinase, CDK10, disclosed herein as: GAAAAGGCGC AGTGGGGCCC GGAGCTGTCA CCCCTGACTC GACGCAGCTT CCGTTCTCCT GGTGACGTCG CCTACAGGAA CCGCCCCAGT GGTCAGCTGC CGCGCTGTTG CTAGGCAACA GCGTGCGAGC TCAGATCAGC GTGGGGTGGA GGAGAAGTGG AGTTTGGAAG TTCAGGGGCA CAGGGGCACA GGCCCACGAC TGCAGCGGGA TGGACCAGTA CTGCATCCTG GGCCGCATCG GGGAGGGCGC CCACGGCATC GTCTTCAAGG CCAAGCACGT GGAGACTGGC GAGATAGTTG CCCTCAAGAA GGTGGCCCTA AGGCGGTTGG AAGACGGCTT CCCTAACCAG GCCCTGCGGG AGATTAAGGC TCTGCAGGAG ATGGAGGACA ATCAGTATGT GGTACAACTG AAGGCTGTGT TCCCACACGG TGGAGGCTTT GTGCTGGCCT TTGAGTTCAT GCTGTCGGAT CTGGCCGAGG TGGTGCGCCA TGCCCAGAGG CCACTAGCCC AGGCACAGGT CAAGAGCTAC CTGCAGATGC TGCTCAAGGG TGTCGCCTTC TGCCATGCCA ACAACATTGT ACATCGGGAC CTGAAACCTG CCAACCTGCT CATCAGCGCC TCAGGCCAGC TCAAGATAGC GGACTTTGGC CTGGCTCGAG TCTTTTCCCC AGACGGCAGC CGCCTCTACA CACACCAGGT GGCCACCAGG TCTGTGGGCT GCATCATGGG GGAGCTGTTG AATGGGTCCC CCCTTTTCCC GGGCAAGAAC GATATTGAAC AGCTTTGCTA TGTGCTTCGC ATCTTGGGCA CCCCAAACCC TCAAGTCTGG CCGGAGCTCA CTGAGCTGCC GGACTACAAC AAGATCTCCT TTAAGGAGCA GGTGCCCATG CCCCTGGAGG AGGTGCTGCC TGACGTCTCT CCCCAGGCAT TGGATCTGCT GGGTCAATTC CTTCTCTACC CTCCTCACCA GCGCATCGCA GCTTCCAAGG CTCTCCTCCA TCAGTACTTC TTCACAGCTC CCCTGCCTGC CCATCCATCT GAGCTGCCGA TTCCTCAGCG TCTAGGGGGA CCTGCCCCCA AGGCCCATCC AGGGCCCCCC CACATCCATG ACTTCCACGT GGACCGGCCT CTTGAGGAGT CGCTGTTGAA CCCAGAGCTG ATTCGGCCCT TCATCCTGGA GGGGTGAGAA GTTGGCCCTG GTCCCGTCTG CCTGCTCCTC AGGACCACTC AGTCCACCTG TTCCTCTGCC ACCTGCCTGG CTTCACCCTC CAAGGCCTCC CCATGGCCAC AGTGGGCCCA CACCACACCC TGCCCCTTAG CCCTTGCGAG GGTTGGTCTC GAGGCAGAGG TCATGTTCCC AGCCAAGAGT ATGAGAACAT CCAGTCGAGC AGAGGAGATT CATGGCCTGT GCTCGGTGAG CCTTACCTTC TGTGTGCTAC TGACGTACCC ATCAGGACAG TGAGCTCTGC TGCCAGTCAA GGCCTGCATA TGCAGAATGA CGATGCCTGC CTTGGTGCTG CTTCCCCGAG TGCTGCCTCC TGGTCAAGGA GAAGTGCAGA GAGTAAGGTG TCCTTATGTT GGAAACTCAA GTGGAAGGAA GATTTGGTTT GGTTTTATTC TCAGAGCCAT TAAACACTAG TTCAGTATGT GAGATATAGA TTCTAAAAAC CTCAGGTGGC
L TCTGCCTTAT GTCTGTTCCT CCTTCATTTC TCTCAAGGGA AATGGCTAAG GTGGCATTGT CTCATGGCTC TCGTTTTTGG GGTCATGGGG AGGGTAGCAC CAGGCATAGC CACTTTTGCC CTGAGGGACT CCTGTGTGCT TCACATCACT GAGCACTCAT TTAGAAGTGA GGGAGACAGA AGTCTAGGCC CAGGGATGGC TCCAGTTGGG GATCCAGCAG GAGACCCTCT GCACATGAGG CTGGTTTACC AACATCTACT CCCTCAGGAT GAGCGTGAGC CAGAAGCAGC TGTGTATTTA AGGAAACAAG CGTTCCTGGA ATTAATTTAT AAATTTAATA AATCCCAATA TAATCCCAAA AAAAAAAAAA AAAAAATTCC TGCGGCCGCA AGGA (SEQ ID NO : 2 ) .
The present invention also relates to a substantially purified novel cyclin-dependent kinase which comprises a novel cyclin binding domain signature sequence (Pro-Asn-Gln-Ala-Leu- Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrlδ as well as the T-loop domain containing the conserved Thrl60/161 residue. Any such nucleic acid may be isolated and characterized from a mammalian cell, including but not limited to human, human and rodent. A human form is an especially preferred form, such as the isolated cDNA exemplified herein as set forth in SEQ ID NO:2 and a dominant negative mutant form as set forth in SEQ ID NO: 12.
The present invention also relates to biologically active fragments and/or mutants of a novel cyclin-dependent kinase which comprises the novel cyclin binding domain (Pro-Asn-Gln-Ala-Leu- Arg-Glu; SEQ ID NO:l), lacks Thrl4 and/or Tyrlδ which make up the conserved ATP binding motif of known CDKs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy- terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use. Any such nucleic acid may be isolated and characterized from a mammalian cell, including but not limited to human, human and rodent, with a human form being an especially preferred form.
A preferred aspect of the present invention is disclosed in SEQ ID NO:3 and Figure 2, the amino acid sequence of CDK10. The open reading frame of the CDK10 coding region runs from nucleotide 210 to nucleotide 1182 of SEQ ID NO:2. The amino acid sequence of the novel cyclin-dependent kinase, CDK10, is disclosed herein as:
MDQYCILGRI GEGAHGIVFK AKHVETGEIV ALKKVALRRL EDGFPNQALR EIKALQEMED NQYWQLKAV FPHGGGFVLA FEFMLSDLAE VVRHAQRPLA QAQVKSYLQM LLKGVAFCHA NNIVHRNLKP ANLLISASGQ LKIADFGLAR VFSPDGSRLY THQVATRSVG CIMGELLNGS PLFPGKNDIE QLCYVLRILG TPNPQVWPEL TELPDYNKIS FKEQVPMPLE EVLPDVSPQA LD LGQFLLY PPHQRIAASK ALLHQYFFTA PLPAHPSELP IPQRLGGPAP KAHPGPPHIH DFHVDRPLEE SLLNPELIRP FILEG ( SEQ ID NO : 3 ) .
Another preferred aspect of the present invention is disclosed in SEQ ID NO:ll, wherein nucleotide δ88 of the wild-type form (SEQ ID NO: 2) is mutated from "G" to "A".
Another preferred aspect of the present invention is the mutant protein, (CDK10-D127N), wherein nucleotide δ88 of SEQ ID NO:ll is mutated from "G" to "A", as compared to the wild-type form (SEQ ID NO:2), which results in a change of Aspl27 to Asnl27 as compared to the wild-type amino acid sequence (SEQ ID NO:3), disclosed as SEQ ID NO:12. The present invention also relates to methods of expressing the cyclin-dependent kinases disclosed herein, assays employing these cyclin-dependent kinases, cells expressing these cyclin-dependent kinases, and compounds identified through the use of these cyclin- dependent kinases, including modulators of the cyclin-dependents kinase either through direct contact with the cyclin-dependent kinase, an associated cyclin, or the CKD/cyclin complex. Such modulators identified in this process are useful as therapeutic agents for controlling cell growth or immune cell proliferation associated with human cancers. Additionally, an isolated and purified CDK10 cDNA which encodes CDK-10 or an active mutant thereof will also be useful for the recombinant production of large quantities of respective protein. The ability to produce large quantities of the protein would be useful for the production of a therapeutic agent comprising the CDK10 protein or a mutant such as the exemplified mutant disclosed herein. A therapeutic agent comprised of CDK10 protein would be useful in the treatment of cell cycle and/or CDK10 related diseases or conditions which are CDKIO responsive or possibly a therapeutic agent comprised of a mutant, including but not limited to CDK10-D127N, which may be useful in the treatment of cell cycle diseases or conditions which are responsive to the regulatory effects of the mutant kinase.
The isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
It is known that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences which contain alternative codons which code for the eventual translation of the identical amino acid. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide. Therefore, this invention is also directed to those DNA sequences which express RNA comprising alternative codons which code for the eventual translation of the identical amino acid, as shown below:
A=Ala=Alanine: codons GCA, GCC, GCG, GCU C=Cys=Cysteine: codons UGC, UGU D=Asp=Aspartic acid: codons GAC, GAU E=Glu=Glutamic acid: codons GAA, GAG F=Phe=Phenylalanine: codons UUC, UUU G=Gly=Glycine: codons GGA, GGC, GGG, GGU H=His =Histidine: codons CAC, CAU I=Ile =Isoleucine: codons AUA, AUC, AUU K=Lys=Lysine: codons AAA, AAG
L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU M=Met=Methionine: codon AUG N=Asp=Asparagine: codons AAC, AAU P=Pro=Proline: codons CCA, CCC, CCG, CCU Q=Gln=Glutamine: codons CAA, CAG
R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU
1 T=Thr=Threonine: codons ACA, ACC, ACG, ACU V=Val=Valine: codons GUA, GUC, GUG, GUU W=Trp=Tryptophan: codon UGG Y=Tyr=Tyrosine: codons UAC, UAU Therefore, the present invention discloses codon redundancy which may result in differing DNA molecules expressing an identical protein. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide. It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally occurring peptide. Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a receptor for a ligand.
It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally- occurring peptide. Methods of altering the DNA sequences include, but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a receptor for a ligand.
As used herein, a "biologically active equivalent" or "functional derivative" of a wild type CDK possesses a biological activity that is substantially similar to the biological activity of the wild type CDKIO protein. The term "functional derivative" is intended to include the "fragments," "mutants," "variants," "degenerate variants," "analogs" and "homologues" or to "chemical derivatives" of the wild type CDKIO protein. The term "fragment" is meant to refer to any polypeptide subset of wild type CDKIO. The term "mutant" is meant to refer to a molecule that may be substantially similar to the wild type form but possesses distinguishing biological characteristics. Such altered characteristics include but are in no way limited to altered enzymatic activity, altered cyclin binding altered substrate binding, altered substrate affinity and altered sensitivity to chemical compounds affecting biological activity. An exemplified mutant is CDK10-D127N, wherein a single base mutation at nucleotide δ88 of SEQ ID NO:2 results in a single amino acid substitution at residue 127, from aspartic acid to asparagine. This mutation alters kinase activity of CDK10-D127N as compared to the wild type CDKIO protein. The term "variant" is meant to refer to a molecule substantially similar in structure and function to either the entire wild type protein or to a fragment thereof. A molecule is "substantially similar" to a wild type CDKlO-like protein if both molecules have substantially similar structures or if both molecules possess similar biological activity. Therefore, if the two molecules possess substantially similar activity, they are considered to be variants even if the structure of one of the molecules is not found in the other or even if the two amino acid sequences are not identical.
The term "analog" refers to a molecule substantially similar in function to either the entire wild type CDKlO-like protein or to a fragment thereof. "Substantial homology" or "substantial similarity", when referring to nucleic acids means that the segments or their complementary strands, when optimally aligned and compared, are identical with appropriate nucleotide insertions or deletions, in at least 7δ% of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize to a strand or its complement.
The term "substantial homology", when referring to polypeptides, indicates that the polypeptide or protein in question exhibits at least about 30% homology with the naturally occurring protein in question, usually at least about 65% homology. The nucleic acids claimed herein may be present in whole cells or in cell lysates or in a partially purified or substantially purified form. A nucleic acid is considered substantially purified when it is purified away from environmental contaminants. Thus, a nucleic acid sequence isolated from cells is considered to be substantially purified when purified from cellular components by standard methods while a chemically synthesized nucleic acid sequence is considered to be substantially purified when purified from its chemical precursors.
Any of a variety of procedures may be used to clone CDKIO. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, Proc. Natl. Acad. Sci.85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of CDKIO cDNA. These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the CDKIO cDNA following the construction of an CDKlO-containing cDNA library in an appropriate expression vector system; (3) screening a CDK10- containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the CDKIO protein; (4) screening a CDKlO-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the CDK10 protein. This partial cDNA is obtained by the specific PCR amplification of CDK10 DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other CDK kinases which are related to the CDK10 protein; (δ) screening an CDKlO-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the CDK10 protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of CDK10 cDNA identified as an EST as described above; or (6) designing δ' and 3' gene specific oligonucleotides using SEQ ID NO:2 as a template so that either the full length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and or genomic libraries in order to - isolate a full length version of the nucleotide sequence encoding CDKIO.
It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cells types or species types, may be useful for isolating a
CDKlO-encoding DNA or a CDKIO homologue. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines other than human cells or tissue such as murine cells, rodent cells or any other such vertebrate host which may contain a CDKlO-encoding DNA. Additionally a CDKIO gene may be isolated by oligonucleotide- or polynucleotide- based hybridization screening of a vertebrate genomic library, including but not limited to a human genomic library, a murine genomic library and a rodent genomic library, as well as concomitant human genomic DNA libraries.
It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have CDKIO activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate a CDKIO cDNA may be done by first measuring cell associated CDKIO activity using any known assay for CDK activity.
Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook, et al., 1989, Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene. It is also readily apparent to those skilled in the art that DNA encoding CDKIO may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in Sambrook, et al., supra.
In order to clone the CDKIO gene by one of the preferred methods, the amino acid sequence or DNA sequence of CDKIO or a homologous protein may be necessary. To accomplish this, the CDKIO or a homologous protein may be purified and partial amino acid sequence determined by automated sequenators. It is not necessary to determine the entire amino acid sequence, but the linear sequence of two regions of 6 to 8 amino acids can be determined for the PCR amplification of a partial CDKIO DNA fragment. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized. Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the CDKIO sequence but others in the set will be capable of hybridizing to CDKIO DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still sufficiently hybridize to the CDKIO DNA to permit identification and isolation of CDKIO encoding DNA. Alternatively, the nucleotide sequence of a region of an expressed sequence may be identified by searching one or more available genomic databases. Gene-specific primers may be used to perform PCR amplification of a cDNA of interest from either a cDNA library or a population of cDNAs. As noted above, the appropriate nucleotide sequence for use in a PCR-based method may be obtained from SEQ ID NO:2, either for the purpose of isolating overlapping δ' and 3' RACE products for generation of a full-length sequence coding for CDKIO, or to isolate a portion of the nucleotide sequence coding for CDKIO for use as a probe to screen one or more cDNA- or genomic-based libraries to isolate a full-length sequence encoding CDKIO or CDKlO-like proteins. In an exemplified method, the RACE PCR technique
(Frohman, et al., 1988, Proc. Natl. Acad. Sci 8δ: 8998-9002) is used for cloning a δ'coding region of CDK10 encoding DNA. First round PCR used adapter-ligated human placenta cDNA template (from Clontech), gene-specific primer PK22L234, (δ'-TGATGCAGCCCACAGACCTG-3'; SEQ ID NO: 4) and an adapter primer API
H (δ'-CCATCCTAATACGACTCACTATAGGGC-3'; SEQ ID NO:δ). PCR amplification was performed using the ElongaseTM. Thermal cycling was completed and a portion of this first PCR reaction was added to a second PCR reaction as DNA template. This PCR reaction also differed from the first PCR reaction in that the nested gene specific primer PK22L161
(δ'-GCCGTCTGGGGAAAAGA-3'; SEQ ID NO:6) and the nested adapter primer AP2 (5'-ACTCACTATAGGGCTCGAGCGGC-3', SEQ ID NO:7) were utilized.
An approximately 600 bp DNA product was identified from a 1% agarose electrophoresis gel, excised, and purified using a Qiagen PCR-spun column (Qiaquick ™). This fragment was used directly for DNA sequencing using PK22L161 and AP2 primers, and for cloning into pCR2.1 using the Invitrogen TA- cloning kit.
A DNA fragment 3' to and overlapping the 600 bp 5' fragment was identified by searching public nucleic acid and protein databases. This 3' fragment is an approximately 1.8 Kb cDNA insert available as a Notl-Hindlll fragment in a typical phagemid vector. This cDNA clone is readily identified by Genbank Accession No. H17727, Image Clone ID No. 60484, Washington University Clone ID No. ym40a06, and GBD Clone ID No. 423294. This cDNA was isolated from a library constructed from human infant brain mRNA. This construct is available from Research Genetics, Inc., 2130 Memorial Parkway SW, Hunstville, AL 3δ801 (http://www. resgen.com).
A full length CDKIO coding region was assembled in pLITMUS28 (New England Biolabs) as an expression cassette with a BamHI site appended just δ' to the ATG translational start codon. A BamHI-Xbal fragment bearing CDK10 was recloned into pcDNA3.1 expression vector (Invitrogen) and a BamHI-Ncol fragment bearing CDK10 was recloned into pBlueBacHis2 baculovirus expression vector (Invitrogen). A similar construct was generated which contains dominant-negative single base pair mutation of CDKIO. This mutant was generated from pLITMUS28::CDK10 using the Stratagene "Quik Change" kit and primers 22U-D127N
(δ'-CAACATTGTACATCGGAACCTGAAACCTGCC-3'; SEQ ID NO: 8) and 22L-D127N (δ'-GGCAGGTTTCAGGTTCC-GATGTACAATGTTG-3'; SEQ ID NO: 9). Both mutant constructions were subcloned into pcDNA3.1 (as a BamHI-Xbal fragment) and pBlueBacHis2 (as a BamHI- Ncol fragment), respectively.
The sequence for the δ' upstream sequences, coding region and 3' untranslated sequences for the human full-length cDNA encoding CDKIO is shown in SEQ ID NO:2. The deduced amino acid sequence of CDKIO from the cloned cDNA is shown in SEQ ID NO:3. Inspection of the determined cDNA sequence reveals the presence of a single open reading frame that encodes a 32δ amino acid protein. The open reading frame of the CDKIO coding region runs from nucleotide 210 to nucleotide 1182 of SEQ ID NO:2.
The nucleotide sequence which encodes a preferred mutant form (Aspl27 to Asnl27), is disclosed as SEQ ID NO:ll. The amino acid sequence for this preferred mutant form, CDK10-D127N, is disclosed in SEQ ID NO:12.
A variety of mammalian expression vectors may be used to express recombinant CDKIO in mammalian cells. Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, blue green algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria- animal cells. An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning
I* vectors, modified cloning vectors, specifically designed plasmids or viruses.
Commercially available mammalian expression vectors which may be suitable for recombinant CDKIO expression, include but are not limited to, pcDNA3.1 (Invitrogen), pBlueBacHis2 (Invitrogen), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Bioloabs), pcDNAI, pcDNAIamp (Invitrogen), pcDNA3 (Invitrogen), pMClneo (Stratagene), pXTl (Stratagene), pSGδ (Stratagene), EBO-pSV2-neo (ATCC 37δ93) pBPV- 1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and λZD3δ (ATCC 37δ6δ).
A variety of bacterial expression vectors may be used to express recombinant CDKIO in bacterial cells. Commercially available bacterial expression vectors which may be suitable for recombinant CDKIO expression include, but are not limited to pCR2.1 (Invitrogen), pETlla (Novagen), lambda gtll (Invitrogen), pcDNAII (Invitrogen), pKK223-3 (Pharmacia).
A variety of fungal cell expression vectors may be used to express recombinant CDK10 in fungal cells. Commercially available fungal cell expression vectors which may be suitable for recombinant CDK10 expression include but are not limited to pYES2 (Invitrogen), Pichia expression vector (Invitrogen).
A variety of insect cell expression vectors may be used to express recombinant receptor in insect cells. Commercially available insect cell expression vectors which may be suitable for recombinant expression of CDK10 include but are not limited to pBlueBacIII and pBlueBacHis2 (Invitrogen).
The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, lipofection, protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce CDK10 protein. Identification of CDK10 expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-CDKlO antibodies.
»?■ Expression of CDKIO DNA may also be performed using in vitro produced synthetic mRNA or native mRNA. Synthetic mRNA or mRNA isolated from CDKIO producing cells can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.
An expression vector containing DNA encoding a CDKlO- like protein may be used for expression of CDKIO in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as E. coli, fungal cells such as yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to Drosophila and silkworm derived cell lines. Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, L cells L-M(TK") (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), Saos-2 (ATCC HTB-8δ), 293 (ATCC CRL lδ73), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 16δ0), COS-7 (ATCC CRL 16δl), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 16δ8), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-δ (ATCC CCL 171).
The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. The expression vector-containing cells are individually analyzed to determine whether they produce CDKIO protein. Identification of CDKIO expressing cells may be done by several means, including but not limited to immunological reactivity with anti-CDKlO antibodies, and the presence of host cell-associated CDK10 activity.
The cloned CDK10 cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector (such as pcDNA3.1, pCR2.1, pBlueBacHis2 and pLITMUS28) containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant CDK10. Techniques for such manipulations can be found described in Sambrook, et al., supra , are discussed at length in the Example section and are well known and easily available to the artisan of ordinary skill in the art.
Expression of CDKIO DNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred. To determine the CDKIO cDNA sequence(s) that yields optimal levels of CDKIO protein, CDKIO cDNA molecules including but not limited to the following can be constructed: the full-length open reading frame of the CDKIO cDNA and various constructs containing portions of the cDNA encoding only specific domains of the protein or rearranged domains of the protein. All constructs can be designed to contain none, all or portions of the 5' and/or 3' untranslated region of CDKIO. CDKIO activity and levels of protein expression can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells. Following determination of the CDKIO cDNA cassette yielding optimal expression in transient assays, this CDKIO cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells. Levels of CDKIO protein in host cells is quantified by a variety of techniques including, but not limited to, immunoaffinity and/or ligand affinity techniques. CDKlO-specific affinity beads or CDKlO-specific antibodies are used to isolate 3δS-methionine labeled or unlabelled CDKIO protein. Labeled CDKIO protein is analyzed by SDS- PAGE. Unlabelled CDKIO protein is detected by Western blotting, ELISA or RIA assays employing CDKIO specific antibodies.
Following expression of CDKIO in a host cell, CDKIO protein may be recovered to provide CDKIO in active form. Several CDKIO purification procedures are available and suitable for use. Recombinant CDKIO may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography.
In addition, recombinant CDKIO can be separated from other cellular proteins by use of an immuno- affinity column made with monoclonal or polyclonal antibodies specific for full length CDKIO, or polypeptide fragments of CDKIO. Additionally, polyclonal or monoclonal antibodies may be raised against a synthetic peptide (usually from about 9 to about 2δ amino acids in length) from a portion of the protein as disclosed in SEQ ID NO:3. Monospecific antibodies to CDKIO are purified from mammalian antisera containing antibodies reactive against CDKIO or are prepared as monoclonal antibodies reactive with CDKIO using the technique of Kohler and Milstein (197δ, Nature 2δ6: 49δ-497). Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for CDKIO. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the CDKIO, as described above. CDKIO specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of CDKIO or CDKIO synthetic peptide either with or without an immune adjuvant.
Preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 μg and about 1000 μg of CDK10 associated with an acceptable immune adjuvant. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA. The initial immunization consists of the CDK10 protein or CDK10 synthetic peptide in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunizaiton. Those animals receiving booster injections are generally given an equal amount of CDK10 in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20°C.
Monoclonal antibodies (mAb) reactive with CDKIO are prepared by immunizing inbred mice, preferably Balb/c, with CDKIO. The mice are immunized by the IP or SC route with about 1 μg to about 100 μg, preferably about 10 μg, of CDKIO in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 μg of CDK10 in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes, from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NSl/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected form growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using CDK10 as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, 1973, Soft Agar Techniques, in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press.
Monoclonal antibodies are produced in vivo by injection of pristine primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x 10" to about 6 x 10" hybridoma cells about 4 days after priming.
Ascites fluid is collected at approximately 8-12 days after cell transfer
X and the monoclonal antibodies are purified by techniques known in the art.
In vitro production of anti-CDKlO mAb is carried out by growing the hydridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.
Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of CDKIO in body fluids or tissue and cell extracts.
It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be utilized to produce antibodies specific for CDKIO polypeptide fragments, or full-length CDKIO polypeptide.
CDKIO antibody affinity columns are made by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine HC1 (pH 8). The column is washed with water followed by 0.23 M glycine HCl (pH 2.6) to remove any non-conjugated antibody or extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing CDKIO or CDKIO fragments are slowly passed through the column. The column is then washed with phosphate buffered saline until the optical density (A280) falls to background, then the protein is eluted with 0.23 M glycine-HCl (pH 2.6). The purified CDK10 protein is then dialyzed against phosphate buffered saline.
The novel CDK10 of the present invention is suitable for use in an assay procedure for the identification of compounds which modulate CDK10 activity. Modulating CDK10 activity, as described herein includes the inhibition or activation of the protein and also includes directly or indirectly affecting the cell cycle regulatory properties associated with CDK10 activity. Compounds which modulate CDKIO activity include agonists, antagonists, inhibitors, activators, and compounds which directly or indirectly affect regulation of the CDKIO activity and/or the CDKlO/cyclin association.
The CDKIO protein kinase of the present invention may be obtained from both native and recombinant sources for use in an assay procedure to identify CDKIO modulators. In general, an assay procedure to identify CDKIO modulators will contain the CDKlO-protein of the present invention, native cyclin protein which will form a CDKlO/cyclin complex, and a test compound or sample which contains a putative CDKIO modulator. The test compounds or samples may be tested directly on, for example, purified CDKIO protein whether native or recombinant, subcellular fractions of CDKlO-producing cells whether native or recombinant, and/or whole cells expressing the CDKIO whether native or recombinant. The test compound or sample may be added to the CDKIO in the presence or absence of a known CDKIO modulator. The modulating activity of the test compound or sample may be determined by, for example, analyzing the ability of the test compound or sample to bind to CDKIO protein, activate the protein, inhibit CDKIO activity, inhibit or enhance the binding of other compounds to the CDKIO protein, modifying receptor regulation, or modifying an intracellular activity.
The identification of modulators of CDKIO activity are useful in treating disease states involving the cell cycle will be useful in controlling cell growth associated with cancer or immune cell proliferation. Other compounds may be useful for stimulating or inhibiting activity of the enzyme. These compounds could be of use in the treatment of diseases in which activation or inactivation of the CDKIO protein results in either cellular proliferation, cell death, nonproliferation, induction of cellular neoplastic transformations or metastatic tumor growth and hence could be used in the prevention and/or treatment of various cancers.
The present invention is also directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding a CDK protein of the present invention or which modulates the function of a such a CDK protein. Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules. Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding the CDK protein, or the function of a CDK protein. Compounds that modulate the expression of DNA or RNA encoding the CDK protein or the biological function thereof may be detected by a variety of assays. The assay may be a simple "yes/no" assay to determine whether there is a change in expression or function. The assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample. Kits containing modified CDKIO, antibodies to CDKIO, or modified CDKIO protein may be prepared by known methods for such uses.
The DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of CDKIO DNA, RNA or protein. The recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of CDKIO. Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further comprise reagents such as recombinant CDKIO protein or anti-CDKlO antibodies suitable for detecting CDKIO. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.
Pharmaceutically useful compositions comprising modulators of CDKIO may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein, DNA, RNA, or modified CDKIO. Therapeutic or diagnostic compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders. The effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
Ά The pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.
The term "chemical derivative" describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half- life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.
Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages. Alternatively, co- administration or sequential administration of other agents may be desirable.
The present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention. The compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents can be administered concurrently, or they each can be administered at separately staggered times.
The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug Isolated and purified CDKIO is also be useful for the recombinant production of large quantities of CDKIO protein. The ability to produce large quantities of the protein would be useful for the production of a therapeutic agent comprising the CDKIO protein. A therapeutic agent comprised of CDKIO protein would be useful in the treatment of cell cycle and/or CDKIO related diseases or conditions which are CDKIO responsive.
By computer analysis of a genomic database, molecular cloning and DNA sequencing a novel member of the human CDK gene family has been identified. This new cDNA fragment encodes a novel cyclin-dependent kinase which comprises a novel cyclin binding domain signature sequence, lacks Thrl4 and/or Tyrlδ within the conserved ATP binding motif of known CDKs, and also lacks the T-loop domain containing the conserved Thrl60/161 residue.
Northern hybridization experiments with RNA from various cell and tissues indicates that CDKIO is expressed in various human tissue, including brain, testis, pituitary gland and adrenal gland derived cells or tissues.
3* The following examples are provided as illustrative of the present invention without, however, limiting the same thereto.
EXAMPLE 1
Isolation and Characterization of DNA Fragments Encoding CDK
A 3' portion of the CDKIO coding region was detected among the Merck-Washington University EST's as δ' EST H17727. EST "H17727" resembled several CDK and MAPK genes. The pH17727 plasmid construct comprising the 3' coding region and 3' untranslated region of CDKIO is contained within a Notl-Hindlll fragment of approximately 1.8 Kb, in a typical phagemid vector. The δ' portion of this fragment overlaps the 3' end of the 600 bp. This cDNA clone is publicly available by Genbank Accession No. H17727, Image Clone ID No. 60484, Washington University Clone ID No. ym40a06, and GBD Clone ID No. 423294. This cDNA was isolated from a library constructed from human infant brain mRNA. This construct is available from Research Genetics, Inc., 2130 Memorial Parkway SW, Hunstville, AL 3δ801 (http://www. resgen.com). The δ' portion of the gene was isolated by performing δ' RACE (Frohman, et al., 1988, Proc. Natl. Acad. Sci.85 8998-9002) using Marathon™-ready human placenta cDNA available from Clontech (Protocol #PTllδ6-l, Catalog #K1802-1). Adapter-ligated double stranded cDNA generated from human placenta mRNA was used as a template for PCR amplification using a gene specific primer PK22L234 (5'-TGATGCAGCCCACAGACCTG-3'; SEQ ID NO: 4) and an adapter primer API (5'-CCATCCTAATACGACTCACTATAGGGC-3' SEQ ID NO:δ). PCR amplification was performed using the ElongaseTM long- PCR enzyme mix (stored in 20mM Tris-HCl (pH 8.0 at 2δ°C), O.lmM EDTA, ImM DTT, stabilizers and δ0%(v/v) glycerol) and PCR reaction buffer obtained from Gibco-BRL. The buffer comprised 300mM Tris-Sθ4 (pH 9.1 at 2δ°C), 90mM (NH4)2S04 and l.δ mM MgS04- Two microliters of Marathon placenta cDNA template and 10 pmoles each of PK22L234 and API were added to the reaction mix and brought to a total volume of 20ml with sterile water. Thermal cycling was (1) 94°C/30sec, 68°C/6min for δ cycles; (2) 94°C/30sec, 64°C/30sec, 68°C/4min for δ cycles; and, (3) 1 94°C/30sec, 62°C/30sec and 68°C/4min for 30 cycles. One microliter from a 1/20 dilution of this first PCR reaction was added to a second PCR reaction as DNA template. This PCR reaction also differed from the first PCR reaction in that nested primers PK22L161 (δ'-GCCGTCTGGGGAAAAGA-3'; SEQ ID NO:6) and AP2
(δ'-ACTCACTATAGGGCTCGAGCGGC-3', SEQ ID NO:7) were used. An approximately 600 bp PCR product was identified from a 1% agarose electrophoresis gel, excised, and purified using a Qiagen PCR-spun column. This fragment was used directly for DNA sequencing using PK22L161 and AP2 oligonucleotide primers.
The Marathon™ -ready human placenta cDNA available from Clontech is enhanced by ligation of a double-stranded, δ' overhang adapter to the double stranded cDNA template. The 3' end of the adapter is blocked by an amine group to prevent extension during PCR amplification. It is within the non-extended 3' region that the API oligo will hybridize. Therefore, API does not hybridize and extend any of the original cDNA template molecules, instead beginning extension and amplification in the second round of PCR.
EXAMPLE 2
Construction of a Full Length DNA Fragment Encoding CDK10
The 3' portion of a DNA fragment which encodes CDK10 is contained within a DNA plasmid vector, pH17727. This insert contains a δ' Xhol site unique to the insert and a Ncol site in the 3' unstranslated region unique to the insert. This Xhol-Ncol fragment was isolated and subcloned into Xhol-Ncol digested pLITMUS28 plasmid DNA (New England Biolabs), resulting in pLITMUS28:H17727.
The 600 bp PCR fragments obtained from δ' RACE were cloned into pCR2.1 (Invitrogen) using the Invitrogen TA-cloning kit as described by the manufacturer. A Pmll restriction site is located at approximately the midpoint of the 600 bp PCR product. The Pmll site was used to construct a wild type form of the 600 bp δ' fragment from 2 independent δ' RACE PCR clones, pPK22bo4 and pPK22do4. The Pmll-BamHI restriction fragment of pPK22bo4 (which contains a mutation 3' to the Pmll site) was replaced with the with the Pmll-BamHI fragment of clone pPK22do4 (which contains a mutation δ' to the Pmll site). The resulting clone, pPK22bo4/do4, overlaps the δ' portion of pH17727 through the unique Xhol restriction site. An Spel- BamHI-Ndel restriction site cluster was appended just δ' to the ATG translational start codon by PCR-amplifying the insert from clone pPK22bo4/do4 using primers PK22L661
(δ*-GCCGTCTGGGGAAAAGA-3'; SEQ ID NO: 6) and PK22U210 (δ*-GGACTAGTGGATCCATATGGACCAGTACTGCATCCT-3'; SEQ ID NO:10). The resulting PCR fragment was digested with Spel and Xhol and ligated into BamHI-XhoI digested pLITMUS28:H17727, resulting in pLITMUS28:CDK10 (Figure 3).
EXAMPLE 3
Construction of CDKIO Mammalian Expression Vector
A BamHI-Xbal fragment from pLITMUS28:CDK10 comprising the CKD10 coding region was subcloned into the mammalian expression vector, pcDNA3.1 (Invitrogen), which was previously digested with BamHI and Xbal. The resulting construct, pcDNA3.1:CDK10, contains a portion of the CMV promoter and a T7 primer site upstream of the CDKIO ATG translational start codon as well as the BGH polyA region downstream of the translational termination codon. Of course, other components to allow growth in E. coli and mammalian cells are present in this vector.
EXAMPLE 4
Construction of CDKIO Baculovirus Transfer Vector
A BamHI-Ncol fragment from pLITMUS28: CDKIO containing the CKDIO coding region was cloned into the baculovirus expression vector, pBlueBacHis2 (Invitrogen), which was previously digested with BamHI and Ncol. The resulting construct, pBBH:CDK10, may be used to express recombinant CDKIO from insect cells by
34 following the manufacturer's instructions (e.g., see Invitrogen Cat. No. V37δ-20 for PBlueBacHis2 A, B, and C).
EXAMPLE δ
Construction of DNA Fragment Encoding a CDKIO Dominant-Negative Mutant
The pLITMUS:CDK10 construct (see Example 2) was mutated to generate a "dominant-negative" single base pair mutation. This mutation was generated from pLITMUS28:CDK10 using the Stratagene "Quik Change" kit and primers 22U-D127N:
(δ'-CAACATTGTACATCGGAACCTGAAACCTGCC-3'; SEQ ID NO:8), and 22L-D127N: (δ'-GGCAGGTTTCAGGTTCCGATGTACAATGTTG-3'; SEQ ID NO: 9), according to the manufacturer's instructions. The dominant-negative mutation changes the codon GAC (at nucleotides δ88- δ90 of SEQ ID NO:2) to AAC (at nucleotides δ88-δ90 of SEQ ID NO: 11), thus deletion essential amino acid Aspl27 to Asnl27 (see SEQ ID NO:12), which inactivates kinase activity (see Example 7 and van den Heuvel & Harlow, 1993, Science 262:20δ0-20δ4). A CDK10-D127N construction was subcloned into pcDNA3.1 (as a BamHI-Xbal fragment), resulting in pcDNA3.1:CDK10-dl27N. A CDK10-D127N construction was also subcloned into pBlueBacHis2 (as a BamHI-Ncol fragment), resulting in PBBH:CDK10-dl27N.
EXAMPLE 6
Tissue Distribution Of CDKIO Expression
Human multiple tissue Northern Blot #7760-1, Human Brain Northern Blot II #7755-1, Human Brain Northern Blot III #7750-1, and "Human multiple tissue Northern Dot Blot were purchased from Clontech. The probe was made by PCR amplifying the Notl-Hindlll insert from pH17727 using the "Universal"
3t> (5*-CCCAGTCACGACGTTGTAAAACG-3'; SEQ ID NO: 13) and "Reverse" (5'-AGCGGATAACAATTTCACACAGG-3': SEQ ID NO: 14) primers from Gibco BRL. Twenty-five ng of the probe was labeled with 32p using a Pharmacia "Ready-to-go" random priming kit and hybridized to the four Northern blots at high stringency according to Clontech instructions.
Figure 4 and Figure δ show Northern data indicating the presence of CDKIO transcripts in a variety of adult human tissue (Figure 4) as well as in specific regions of the adult and fetal human brain (Figure δ). This data shows increased expression levels in the testis as well as in pituitary and adrenal glands. Expression in various regions of the brain was relatively constant, with increased expression seen in the frontal and temporal lobes and the cerebral cortex.
EXAMPLE 7
Effect of CDK:D127N on Cell Growth
Human osteosarcoma cell line Saos2 (ATCC HBT-8δ) was grown in DMEM high glucose medium + glutamine +10% fetal calf serum (in concentrations as recommended by Gibco-BRL). Two replicates of the experiment were performed sequentially. Cells were split 1:6 into 10 cm culture dishes two days prior to transfection. Transfection was performed using the CaP04 method according to Chen and Okayama (1987, Mol. and Cell. Biol. 7:-274δ-27δ2). Ten ug of each plasmid DNA (pcDNA3.1, pcDNA3:CDK10, pcDNA3:CDK10-D127N) was transfected into ~60% confluent cells in each 10 cm dish. Cells were rinsed 2x with Dulbecco's PBS (Gibco-BRL) and 10 mL fresh medium was added. After two days, cells were trypsinized and plated in 12 well dishes in fresh medium + δOOug/mL geneticin (Gibco-BRL). At 11 and 16 days after plating, colony counts were made to determine how many transfected cells were capable of growth and colony formation (Table 1). This data indicates that expression of the kinase inactive "dominant- negative" form of CDK10 (i.e., CDK10-D127N) impairs colony formation by analogy to the data presented in van den Heuvel and Harlow (1993, Science 262: 20δ0-20δ4). TABLE 1
Day 11 (Colonies) Day 16 (# Colonies)
Figure imgf000034_0001
EXAMPLE 8
Specific Effect of the Dominant Mutant CDK:D127N on Expression of Cell Cycle Genes
HeLa cervical carcinoma cells were treated for 48 hours with a control adenovirus deleted for the El and E3 genes or the same adenovirus which comprised the construct encoding CDK10-D127N. Western blots were performed with a rabbit antibody raised to the C-terminal 25 amino acids of the CDKIO protein (amino acid 301 - amino acid 325 of SEQ ID NO: 3). The cell line transfected with Ad/CDKIO- D127N expressed CDK10-D127N at a δO-fold higher level than endogenous, wild type CDKIO. The two infected cell populations were subjected to mRNA isolations and probes were prepared for gene expression DNA chip studies essentially as described by Lockhart, et al. (1996, Nature Biotechnology 14:1675-1680). Among the genes which were suppressed at the mRNA level by CDK10-D127N are summarized in Table 2.
3 TABLE 2
GENE Ad/CDKIO- Ad- Control
D127N
CDC25b 8.3 19.1
CDK7 3.1 8.5
CKSl 26.3 82.δ
CKS2 11.6 98.3
Cyclin B 16.δ 41.5
Cyclin Dl 4.5 11.5 poly- 186.5 664.5
Ubiquitin
1 Quantified arbitrary expression units measured from the fluorescence image of the oligonucleotide array.
These data indicate a cell cycle block by the dominant-negative mutant gene, CDK10-D127N, which shows the importance of the CDKIO protein to the cell cycle. Cell cycle analysis (using a fluorescence-activated cell sorter, or FACS) of cells treated for 48 hours with the two viruses indicate that cells are not blocked in any particular phase of the cell cycle.
The data reported in the above Example sections show the importance of CDKIO in the cell cycle. Therefore, a therapeutic agent comprising the CDKIO protein would be useful in the treatment of cell cycle and/or CDKIO related diseases or conditions which are CDKIO responsive as well as showing a potential use for a dominant-negative mutant such as CDK10-D127N, which may be useful in the treatment of cell cycle diseases or conditions which are responsive to the mtuant proteins ability to regulate a phase or phases of the cell cycle.
£* SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Gerhold, David L. (ii) TITLE OF INVENTION: CYCLIN-DEPENDENT PROTEIN KINASE (iii) NUMBER OF SEQUENCES: 14
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Merck & Co . , Inc.
(B) STREET: P.O. Box 2000, RY60-30
(C) CITY: Rahway
(D) STATE: NJ
(E) COUNTRY: US
(F) ZIP: 07065-0907
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Hand, J. Mark
(B) REGISTRATION NUMBER: 36,545
(C) REFERENCE/DOCKET NUMBER: 19885Y
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 732/594-3905
(B) TELEFAX: 732/594-4720
(2) INFORMATION FOR SEQ ID NO : 1 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 :
Pro Asn Gin Ala Leu Arg Glu 1 5
^ (2) INFORMATION FOR SEQ ID NO : 2 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2074 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : double
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
GAAAAGGCGC AGTGGGGCCC GGAGCTGTCA CCCCTGACTC GACGCAGCTT CCGTTCTCCT 60
GGTGACGTCG CCTACAGGAA CCGCCCCAGT GGTCAGCTGC CGCGCTGTTG CTAGGCAACA 120
GCGTGCGAGC TCAGATCAGC GTGGGGTGGA GGAGAAGTGG AGTTTGGAAG TTCAGGGGCA 180
CAGGGGCACA GGCCCACGAC TGCAGCGGGA TGGACCAGTA CTGCATCCTG GGCCGCATCG 240
GGGAGGGCGC CCACGGCATC GTCTTCAAGG CCAAGCACGT GGAGACTGGC GAGATAGTTG 300
CCCTCAAGAA GGTGGCCCTA AGGCGGTTGG AAGACGGCTT CCCTAACCAG GCCCTGCGGG 360
AGATTAAGGC TCTGCAGGAG ATGGAGGACA ATCAGTATGT GGTACAACTG AAGGCTGTGT 420
TCCCACACGG TGGAGGCTTT GTGCTGGCCT TTGAGTTCAT GCTGTCGGAT CTGGCCGAGG 480
TGGTGCGCCA TGCCCAGAGG CCACTAGCCC AGGCACAGGT CAAGAGCTAC CTGCAGATGC 540
TGCTCAAGGG TGTCGCCTTC TGCCATGCCA ACAACATTGT ACATCGGGAC CTGAAACCTG 600
CCAACCTGCT CATCAGCGCC TCAGGCCAGC TCAAGATAGC GGACTTTGGC CTGGCTCGAG 660
TCTTTTCCCC AGACGGCAGC CGCCTCTACA CACACCAGGT GGCCACCAGG TCTGTGGGCT 720
GCATCATGGG GGAGCTGTTG AATGGGTCCC CCCTTTTCCC GGGCAAGAAC GATATTGAAC 780
AGCTTTGCTA TGTGCTTCGC ATCTTGGGCA CCCCAAACCC TCAAGTCTGG CCGGAGCTCA 840
CTGAGCTGCC GGACTACAAC AAGATCTCCT TTAAGGAGCA GGTGCCCATG CCCCTGGAGG 900
AGGTGCTGCC TGACGTCTCT CCCCAGGCAT TGGATCTGCT GGGTCAATTC CTTCTCTACC 960
CTCCTCACCA GCGCATCGCA GCTTCCAAGG CTCTCCTCCA TCAGTACTTC TTCACAGCTC 1020
CCCTGCCTGC CCATCCATCT GAGCTGCCGA TTCCTCAGCG TCTAGGGGGA CCTGCCCCCA 1080
AGGCCCATCC AGGGCCCCCC CACATCCATG ACTTCCACGT GGACCGGCCT CTTGAGGAGT 1140
CGCTGTTGAA CCCAGAGCTG ATTCGGCCCT TCATCCTGGA GGGGTGAGAA GTTGGCCCTG 1200
GTCCCGTCTG CCTGCTCCTC AGGACCACTC AGTCCACCTG TTCCTCTGCC ACCTGCCTGG 1260
CTTCACCCTC CAAGGCCTCC CCATGGCCAC AGTGGGCCCA CACCACACCC TGCCCCTTAG 1320
CCCTTGCGAG GGTTGGTCTC GAGGCAGAGG TCATGTTCCC AGCCAAGAGT ATGAGAACAT 1380 CCAGTCGAGC AGAGGAGATT CATGGCCTGT GCTCGGTGAG CCTTACCTTC TGTGTGCTAC 1440
TGACGTACCC ATCAGGACAG TGAGCTCTGC TGCCAGTCAA GGCCTGCATA TGCAGAATGA 1500
CGATGCCTGC CTTGGTGCTG CTTCCCCGAG TGCTGCCTCC TGGTCAAGGA GAAGTGCAGA 1560
GAGTAAGGTG TCCTTATGTT GGAAACTCAA GTGGAAGGAA GATTTGGTTT GGTTTTATTC 1620
TCAGAGCCAT TAAACACTAG TTCAGTATGT GAGATATAGA TTCTAAAAAC CTCAGGTGGC 1680
TCTGCCTTAT GTCTGTTCCT CCTTCATTTC TCTCAAGGGA AATGGCTAAG GTGGCATTGT 1740
CTCATGGCTC TCGTTTTTGG GGTCATGGGG AGGGTAGCAC CAGGCATAGC CACTTTTGCC 1800
CTGAGGGACT CCTGTGTGCT TC CATCACT GAGCACTCAT TTAGAAGTGA GGGAGACAGA 1860
AGTCTAGGCC CAGGGATGGC TCCAGTTGGG GATCCAGCAG GAGACCCTCT GCACATGAGG 1920
CTGGTTTACC AACATCTACT CCCTCAGG T GAGCGTGAGC CAGAAGCAGC TGTGTATTTA 1980
AGGAAACAAG CGTTCCTGGA ATTAATTTAT AAATTTAATA AATCCCAATA TAATCCCAAA 2040
AAAAAAAAAA AAAAAATTCC TGCGGCCGCA AGGA 2074 (2) INFORMATION FOR SEQ ID NO : 3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 325 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
Met Asp Gin Tyr Cys lie Leu Gly Arg lie Gly Glu Gly Ala His Gly 1 5 - 10 15
He Val Phe Lys Ala Lys His Val Glu Thr Gly Glu He Val Ala Leu 20 25 30
Lys Lys Val Ala Leu Arg Arg Leu Glu Asp Gly Phe Pro Asn Gin Ala 35 40 45
Leu Arg Glu He Lys Ala Leu Gin Glu Met Glu Asp Asn Gin Tyr Val 50 55 60
Val Gin Leu Lys Ala Val Phe Pro His Gly Gly Gly Phe Val Leu Ala 65 70 75 80
Phe Glu Phe Met Leu Ser Asp Leu Ala Glu Val Val Arg His Ala Gin 85 90 95
Arg Pro Leu Ala Gin Ala Gin Val Lys Ser Tyr Leu Gin Met Leu Leu 100 105 110
3U Lys Gly Val Ala Phe Cys His Ala Asn Asn He Val His Arg Asp Leu 115 120 125
Lys Pro Ala Asn Leu Leu He Ser Ala Ser Gly Gin Leu Lys He Ala 130 135 140
Asp Phe Gly Leu Ala Arg Val Phe Ser Pro Asp Gly Ser Arg Leu Tyr 145 150 155 160
Thr His Gin Val Ala Thr Arg Ser Val Gly Cys He Met Gly Glu Leu 165 170 175
Leu Asn Gly Ser Pro Leu Phe Pro Gly Lys Asn Asp He Glu Gin Leu 180 185 190
Cys Tyr Val Leu Arg He Leu Gly Thr Pro Asn Pro Gin Val Trp Pro 195 200 205
Glu Leu Thr Glu Leu Pro Asp Tyr Asn Lys He Ser Phe Lys Glu Gin 210 215 220
Val Pro Met Pro Leu Glu Glu Val Leu Pro Asp Val Ser Pro Gin Ala 225 230 235 240
Leu Asp Leu Leu Gly Gin Phe Leu Leu Tyr Pro Pro His Gin Arg He 245 250 255
Ala Ala Ser Lys Ala Leu Leu His Gin Tyr Phe Phe Thr Ala Pro Leu 260 265 270
Pro Ala His Pro Ser Glu Leu Pro He Pro Gin Arg Leu Gly Gly Pro 275 280 285
Ala Pro Lys Ala His Pro Gly Pro Pro His He His Asp Phe His Val 290 295 300
Asp Arg Pro Leu Glu Glu Ser Leu Leu Asn Pro Glu Leu He Arg Pro 305 310 315 320
Phe He Leu Glu Gly 325
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
3? (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: TGATGCAGCC CACAGACCTG 20
(2) INFORMATION FOR SEQ ID NO : 5 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 : CCATCCTAAT ACGACTCACT ATAGGGC 27
(2) INFORMATION FOR SEQ ID NO : 6 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : GCCGTCTGGG GAAAAGA 17
(2) INFORMATION FOR SEQ ID NO : 7 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7 : ACTCACTATA GGGCTCGAGC GGC 23
IV (2) INFORMATION FOR SEQ ID NO : 8 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide'
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8 : CAACATTGTA CATCGGAACC TGAAACCTGC C 31
(2) INFORMATION FOR SEQ ID NO : 9 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9 : GGCAGGTTTC AGGTTCCGAT GTACAATGTT G 31
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: GGACTAGTGG ATCCATATGG ACCAGTACTG CATCCT 36
3 (2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2074 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
GAAAAGGCGC AGTGGGGCCC GGAGCTGTCA CCCCTGACTC GACGCAGCTT CCGTTCTCCT 60
GGTGACGTCG CCTACAGGAA CCGCCCCAGT GGTCAGCTGC CGCGCTGTTG CTAGGCAACA 120
GCGTGCGAGC TCAGATCAGC GTGGGGTGGA GGAGAAGTGG AGTTTGGAAG TTCAGGGGCA 180
CAGGGGCACA GGCCCACGAC TGCAGCGGGA TGGACCAGTA CTGCATCCTG GGCCGCATCG 240
GGGAGGGCGC CCACGGCATC GTCTTCAAGG CCAAGCACGT GGAGACTGGC GAGATAGTTG 300
CCCTCAAGAA GGTGGCCCTA AGGCGGTTGG AAGACGGCTT CCCTAACCAG GCCCTGCGGG 360
AGATTAAGGC TCTGCAGGAG ATGGAGGACA ATCAGTATGT GGTACAACTG AAGGCTGTGT 420
TCCCACACGG TGGAGGCTTT GTGCTGGCCT TTGAGTTCAT GCTGTCGGAT CTGGCCGAGG 480
TGGTGCGCCA TGCCCAGAGG CCACTAGCCC AGGCACAGGT CAAGAGCTAC CTGCAGATGC 540
TGCTCAAGGG TGTCGCCTTC TGCCATGCCA ACAACATTGT ACATCGGAAC CTGAAACCTG 600
CCAACCTGCT CATCAGCGCC TCAGGCCAGC TCAAGATAGC GGACTTTGGC CTGGCTCGAG 660
TCTTTTCCCC AGACGGCAGC CGCCTCTACA CACACCAGGT GGCCACCAGG TCTGTGGGCT 720
GCATCATGGG GGAGCTGTTG AATGGGTCCC CCCTTTTCCC GGGCAAGAAC GATATTGAAC 780
AGCTTTGCTA TGTGCTTCGC ATCTTGGGCA CCCCAAACCC TCAAGTCTGG CCGGAGCTCA 840
CTGAGCTGCC GGACTACAAC AAGATCTCCT TTAAGGAGCA GGTGCCCATG CCCCTGGAGG 900
AGGTGCTGCC TGACGTCTCT CCCCAGGCAT TGGATCTGCT GGGTCAATTC CTTCTCTACC 960
CTCCTCACCA GCGCATCGCA GCTTCCAAGG CTCTCCTCCA TCAGTACTTC TTCACAGCTC 1020
CCCTGCCTGC CCATCCATCT GAGCTGCCGA TTCCTCAGCG TCTAGGGGGA CCTGCCCCCA 1080
AGGCCCATCC AGGGCCCCCC CACATCCATG ACTTCCACGT GGACCGGCCT CTTGAGGAGT 1140
CGCTGTTGAA CCCAGAGCTG ATTCGGCCCT TCATCCTGGA GGGGTGAGAA GTTGGCCCTG 1200
GTCCCGTCTG CCTGCTCCTC AGGACCACTC AGTCCACCTG TTCCTCTGCC ACCTGCCTGG 1260
CTTCACCCTC CAAGGCCTCC CCATGGCCAC AGTGGGCCCA CACCACACCC TGCCCCTTAG 1320
CCCTTGCGAG GGTTGGTCTC GAGGCAGAGG TCATGTTCCC AGCCAAGAGT ATGAGAACAT 1380 CCAGTCGAGC AGAGGAGATT CATGGCCTGT GCTCGGTGAG CCTTACCTTC TGTGTGCTAC 1440
TGACGTACCC ATCAGGACAG TGAGCTCTGC TGCCAGTCAA GGCCTGCATA TGCAGAATGA 1500
CGATGCCTGC CTTGGTGCTG CTTCCCCGAG TGCTGCCTCC TGGTCAAGGA GAAGTGCAGA 1560
GAGTAAGGTG TCCTTATGTT GGAAACTCAA GTGGAAGGAA GATTTGGTTT GGTTTTATTC 1620
TCAGAGCCAT TAAACACTAG TTCAGTATGT GAGATATAGA TTCTAAAAAC CTCAGGTGGC 1680
TCTGCCTTAT GTCTGTTCCT CCTTCATTTC TCTCAAGGGA AATGGCTAAG GTGGCATTGT 1740
CTCATGGCTC TCGTTTTTGG GGTCATGGGG AGGGTAGCAC CAGGCATAGC CACTTTTGCC 1800
CTGAGGGACT CCTGTGTGCT TCACATC CT GAGCACTCAT TTAGAAGTGA GGGAGACAGA 1860
AGTCTAGGCC CAGGGATGGC TCCAGTTGGG GATCCAGCAG GAGACCCTCT GCACATGAGG 1920
CTGGTTTACC AACATCTACT CCCTCAGGAT GAGCGTGAGC CAGAAGCAGC TGTGTATTTA 1980
AGGAAACAAG CGTTCCTGGA ATTAATTTAT AAATTTAATA AATCCCAATA TAATCCCAAA 2040
AAAAAAAAAA AAAAAATTCC TGCGGCCGCA AGGA 2074 (2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 325 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
Met Asp Gin Tyr Cys He Leu Gly Arg He Gly Glu Gly Ala His Gly 1 5 - 10 15
He Val Phe Lys Ala Lys His Val Glu Thr Gly Glu He Val Ala Leu 20 25 30
Lys Lys Val Ala Leu Arg Arg Leu Glu Asp Gly Phe Pro Asn Gin Ala 35 40 45
Leu Arg Glu He Lys Ala Leu Gin Glu Met Glu Asp Asn Gin Tyr Val 50 55 60
Val Gin Leu Lys Ala Val Phe Pro His Gly Gly Gly Phe Val Leu Ala 65 70 75 80
Phe Glu Phe Met Leu Ser Asp Leu Ala Glu Val Val Arg His Ala Gin 85 90 95
Arg Pro Leu Ala Gin Ala Gin Val Lys Ser Tyr Leu Gin Met Leu Leu 100 105 110
HI Lys Gly Val Ala Phe Cys His Ala Asn Asn He Val His Arg Asn Leu 115 120 125
Lys Pro Ala Asn Leu Leu He Ser Ala Ser Gly Gin Leu Lys He Ala 130 135 140
Asp Phe Gly Leu Ala Arg Val Phe Ser Pro Asp Gly Ser Arg Leu Tyr 145 150 155 160
Thr His Gin Val Ala Thr Arg Ser Val Gly Cys He Met Gly Glu Leu 165 170 175
Leu Asn Gly Ser Pro Leu Phe Pro Gly Lys Asn Asp He Glu Gin Leu 180 185 190
Cys Tyr Val Leu Arg He Leu Gly Thr Pro Asn Pro Gin Val Trp Pro 195 200 205
Glu Leu Thr Glu Leu Pro Asp Tyr Asn Lys He Ser Phe Lys Glu Gin 210 215 220
Val Pro Met Pro Leu Glu Glu Val Leu Pro Asp Val Ser Pro Gin Ala 225 230 235 240
Leu Asp Leu Leu Gly Gin Phe Leu Leu Tyr Pro Pro His Gin Arg He 245 250 255
Ala Ala Ser Lys Ala Leu Leu His Gin Tyr Phe Phe Thr Ala Pro Leu 260 265 270
Pro Ala His Pro Ser Glu Leu Pro He Pro Gin Arg Leu Gly Gly Pro 275 280 285
Ala Pro Lys Ala His Pro Gly Pro Pro His He His Asp Phe His Val 290 295 300
Asp Arg Pro Leu Glu Glu Ser Leu Leu Asn Pro Glu Leu He Arg Pro 305 310 315 320
Phe He Leu Glu Gly 325
(2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
H (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: CCCAGTCACG ACGTTGTAAA ACG 23
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: AGCGGATAAC AATTTCACAC AGG 23
u3

Claims

WHAT IS CLAIMED IS:
1. A purified DNA molecule encoding a human cyclin dependent kinase wherein said protein comprises the peptide motif
Pro-Asn-Gln-Ala-Leu-Arg-Glu at the amino terminal region of the protein for cyclin binding.
2. A purified DNA molecule of Claim 1 wherein said protein lacks a conserved threonine residue and conserved tyrosine residue within a conserved ATP-binding motif at the amino terminal region of said protein.
3. A purified DNA molecule of Claim 2 wherein said protein lack a conserved T-loop domain at the carboxy terminal region of said protein.
4. A purified DNA molecule of Claim 3 which comprises the nucleotide sequence as follows: GAAAAGGCGC AGTGGGGCCC GGAGCTGTCA CCCCTGACTC GACGCAGCTT CCGTTCTCCT GGTGACGTCG CCTACAGGAA CCGCCCCAGT GGTCAGCTGC CGCGCTGTTG CTAGGCAACA GCGTGCGAGC TCAGATCAGC GTGGGGTGGA GGAGAAGTGG AGTTTGGAAG TTCAGGGGCA CAGGGGCACA GGCCCACGAC TGCAGCGGGA TGGACCAGTA CTGCATCCTG GGCCGCATCG GGGAGGGCGC CCACGGCATC GTCTTCAAGG CCAAGCACGT GGAGACTGGC GAGATAGTTG CCCTCAAGAA GGTGGCCCTA AGGCGGTTGG AAGACGGCTT CCCTAACCAG GCCCTGCGGG AGATTAAGGC TCTGCAGGAG ATGGAGGACA ATCAGTATGT GGTACAACTG AAGGCTGTGT TCCCACACGG TGGAGGCTTT GTGCTGGCCT TTGAGTTCAT GCTGTCGGAT CTGGCCGAGG TGGTGCGCCA TGCCCAGAGG CCACTAGCCC AGGCACAGGT CAAGAGCTAC CTGCAGATGC TGCTCAAGGG TGTCGCCTTC TGCCATGCCA ACAACATTGT ACATCGGGAC CTGAAACCTG CCAACCTGCT CATCAGCGCC TCAGGCCAGC TCAAGATAGC GGACTTTGGC CTGGCTCGAG TCTTTTCCCC AGACGGCAGC CGCCTCTACA CACACCAGGT GGCCACCAGG TCTGTGGGCT GCATCATGGG GGAGCTGTTG AATGGGTCCC CCCTTTTCCC GGGCAAGAAC GATATTGAAC AGCTTTGCTA TGTGCTTCGC ATCTTGGGCA CCCCAAACCC TCAAGTCTGG CCGGAGCTCA CTGAGCTGCC GGACTACAAC AAGATCTCCT TTAAGGAGCA GGTGCCCATG CCCCTGGAGG AGGTGCTGCC TGACGTCTCT CCCCAGGCAT TGGATCTGCT GGGTCAATTC CTTCTCTACC CTCCTCACCA GCGCATCGCA GCTTCCAAGG CTCTCCTCCA TCAGTACTTC TTCACAGCTC CCCTGCCTGC CCATCCATCT GAGCTGCCGA TTCCTCAGCG TCTAGGGGGA CCTGCCCCCA
H4 AGGCCCATCC AGGGCCCCCC CACATCCATG ACTTCCACGT GGACCGGCCT CTTGAGGAGT CGCTGTTGAA CCCAGAGCTG ATTCGGCCCT TCATCCTGGA GGGGTGAGAA GTTGGCCCTG GTCCCGTCTG CCTGCTCCTC AGGACCACTC AGTCCACCTG TTCCTCTGCC ACCTGCCTGG CTTCACCCTC CAAGGCCTCC CCATGGCCAC AGTGGGCCCA CACCACACCC TGCCCCTTAG CCCTTGCGAG GGTTGGTCTC GAGGCAGAGG TCATGTTCCC AGCCAAGAGT ATGAGAACAT CCAGTCGAGC AGAGGAGATT CATGGCCTGT GCTCGGTGAG CCTTACCTTC TGTGTGCTAC TGACGTACCC ATCAGGACAG TGAGCTCTGC TGCCAGTCAA GGCCTGCATA TGCAGAATGA CGATGCCTGC CTTGGTGCTG CTTCCCCGAG TGCTGCCTCC TGGTCAAGGA GAAGTGCAGA GAGTAAGGTG TCCTTATGTT GGAAACTCAA GTGGAAGGAA GATTTGGTTT GGTTTTATTC TCAGAGCCAT TAAACACTAG TTCAGTATGT GAGATATAGA TTCTAAAAAC CTCAGGTGGC TCTGCCTTAT GTCTGTTCCT CCTTCATTTC TCTCAAGGGA AATGGCTAAG GTGGCATTGT CTCATGGCTC TCGTTTTTGG GGTCATGGGG AGGGTAGCAC CAGGCATAGC CACTTTTGCC CTGAGGGACT CCTGTGTGCT TCACATCACT GAGCACTCAT TTAGAAGTGA GGGAGACAGA AGTCTAGGCC CAGGGATGGC TCCAGTTGGG GATCCAGCAG GAGACCCTCT GCACATGAGG CTGGTTTACC AACATCTACT CCCTCAGGAT GAGCGTGAGC CAGAAGCAGC TGTGTATTTA AGGAAACAAG CGTTCCTGGA ATTAATTTAT AAATTTAATA AATCCCAATA TAATCCCAAA AAAAAAAAAA AAAAAATTCC TGCGGCCGCA AGGA, set forth as SEQ ID NO:2
δ. A DNA molecule of Claim 4 which comprises from about nucleotide 210 to about nucleotide 118δ of SEQ ID NO:2.
6. A purified DNA molecule encoding a human cyclin dependent kinase wherein said DNA molecule encodes a protein comprising the amino acid sequence as follows:
Met Asp Gin Tyr Cys He Leu Gly Arg He Gly Glu Gly Ala His Gly He Val Phe Lys Ala Lys His Val Glu Thr Gly Glu He Val Ala Leu Lys Lys Val Ala Leu Arg Arg Leu Glu Asp Gly Phe Pro Asn Gin Ala Leu Arg Glu He Lys Ala Leu Gin Glu Met Glu Asp Asn Gin Tyr Val Val Gin Leu Lys Ala Val Phe Pro His Gly Gly Gly Phe Val Leu Ala Phe Glu Phe Met Leu Ser Asp Leu Ala Glu Val Val Arg His Ala Gin Arg Pro Leu Ala Gin Ala Gin Val Lys Ser Tyr Leu Gin Met Leu Leu Lys Gly Val Ala Phe Cys His Ala Asn Asn He Val His Arg Asp Leu Lys Pro Ala Asn Leu Leu He Ser Ala Ser Gly Gin Leu Lys He Ala Asp Phe Gly Leu Ala Arg Val Phe Ser Pro Asp Gly Ser Arg Leu Tyr Thr His Gin Val Ala Thr Arg Ser Val Gly Cys He Met Gly Glu Leu Leu Asn Gly Ser Pro Leu Phe Pro Gly Lys Asn Asp He Glu Gin Leu Cys Tyr Val Leu Arg He Leu Gly Thr Pro Asn Pro Gin Val Trp Pro
Glu Leu Thr Glu Leu Pro Asp Tyr Asn Lys He Ser Phe Lys Glu Gin
Val Pro Met Pro Leu Glu Glu Val Leu Pro Asp Val Ser Pro Gin Ala
Leu Asp Leu Leu Gly Gin Phe Leu Leu Tyr Pro Pro His Gin Arg He Ala Ala Ser Lys Ala Leu Leu His Gin Tyr Phe Phe Thr Ala Pro Leu
Pro Ala His Pro Ser Glu Leu Pro He Pro Gin Arg Leu Gly Gly Pro
Ala Pro Lys Ala His Pro Gly Pro Pro His He His Asp Phe His Val
Asp Arg Pro Leu Glu Glu Ser Leu Leu Asn Pro Glu Leu He Arg Pro
Phe He Leu Glu Gly, set forth as SEQ ID N0:3.
7. An expression vector for the expression of a human cyclin dependent kinase in a recombinant host cell wherein said expression vector comprises the DNA molecule of Claim 4.
8. The expression vector of Claim 7 which is selected from the group consisting of pLITMUS28:CDK10, pcDNA3.1:CDK10, and pBBH:CDK10.
9. A host cell which expresses a recombinant human cyclin dependent kinase wherein said host cell contains the expression vector of Claim 7.
10. A host cell which expresses a recombinant human cyclin dependent kinase wherein said host cell contains the expression vector of Claim 8.
11. A purified DNA molecule which comprises the nucleotide sequence as follows: GAAAAGGCGC AGTGGGGCCC GGAGCTGTCA CCCCTGACTC GACGCAGCTT CCGTTCTCCT GGTGACGTCG CCTACAGGAA CCGCCCCAGT GGTCAGCTGC CGCGCTGTTG CTAGGCAACA GCGTGCGAGC TCAGATCAGC GTGGGGTGGA GGAGAAGTGG AGTTTGGAAG TTCAGGGGCA CAGGGGCACA GGCCCACGAC TGCAGCGGGA TGGACCAGTA CTGCATCCTG GGCCGCATCG GGGAGGGCGC CCACGGCATC GTCTTCAAGG CCAAGCACGT GGAGACTGGC GAGATAGTTG CCCTCAAGAA GGTGGCCCTA AGGCGGTTGG AAGACGGCTT CCCTAACCAG GCCCTGCGGG AGATTAAGGC TCTGCAGGAG ATGGAGGACA ATCAGTATGT GGTACAACTG AAGGCTGTGT TCCCACACGG TGGAGGCTTT GTGCTGGCCT TTGAGTTCAT GCTGTCGGAT CTGGCCGAGG TGGTGCGCCA TGCCCAGAGG CCACTAGCCC AGGCACAGGT CAAGAGCTAC CTGCAGATGC TGCTCAAGGG TGTCGCCTTC TGCCATGCCA ACAACATTGT ACATCGGAAC CTGAAACCTG CCAACCTGCT CATCAGCGCC TCAGGCCAGC TCAAGATAGC GGACTTTGGC CTGGCTCGAG TCTTTTCCCC AGACGGCAGC CGCCTCTACA CACACCAGGT GGCCACCAGG TCTGTGGGCT GCATCATGGG GGAGCTGTTG AATGGGTCCC CCCTTTTCCC GGGCAAGAAC GATATTGAAC AGCTTTGCTA TGTGCTTCGC ATCTTGGGCA CCCCAAACCC TCAAGTCTGG CCGGAGCTCA CTGAGCTGCC GGACTACAAC AAGATCTCCT TTAAGGAGCA GGTGCCCATG CCCCTGGAGG AGGTGCTGCC TGACGTCTCT CCCCAGGCAT TGGATCTGCT GGGTCAATTC CTTCTCTACC CTCCTCACCA GCGCATCGCA GCTTCCAAGG CTCTCCTCCA TCAGTACTTC TTCACAGCTC CCCTGCCTGC CCATCCATCT GAGCTGCCGA TTCCTCAGCG TCTAGGGGGA CCTGCCCCCA AGGCCCATCC AGGGCCCCCC CACATCCATG ACTTCCACGT GGACCGGCCT CTTGAGGAGT CGCTGTTGAA CCCAGAGCTG ATTCGGCCCT TCATCCTGGA GGGGTGAGAA GTTGGCCCTG GTCCCGTCTG CCTGCTCCTC AGGACCACTC AGTCCACCTG TTCCTCTGCC ACCTGCCTGG CTTCACCCTC CAAGGCCTCC CCATGGCCAC AGTGGGCCCA CACCACACCC TGCCCCTTAG CCCTTGCGAG GGTTGGTCTC GAGGCAGAGG TCATGTTCCC AGCCAAGAGT ATGAGAACAT CCAGTCGAGC AGAGGAGATT CATGGCCTGT GCTCGGTGAG CCTTACCTTC TGTGTGCTAC TGACGTACCC ATCAGGACAG TGAGCTCTGC TGCCAGTCAA GGCCTGCATA TGCAGAATGA CGATGCCTGC CTTGGTGCTG CTTCCCCGAG TGCTGCCTCC TGGTCAAGGA GAAGTGCAGA GAGTAAGGTG TCCTTATGTT GGAAACTCAA GTGGAAGGAA GATTTGGTTT GGTTTTATTC TCAGAGCCAT TAAACACTAG TTCAGTATGT GAGATATAGA TTCTAAAAAC CTCAGGTGGC TCTGCCTTAT GTCTGTTCCT CCTTCATTTC TCTCAAGGGA AATGGCTAAG GTGGCATTGT CTCATGGCTC TCGTTTTTGG GGTCATGGGG AGGGTAGCAC CAGGCATAGC CACTTTTGCC CTGAGGGACT CCTGTGTGCT TCACATCACT GAGCACTCAT TTAGAAGTGA GGGAGACAGA AGTCTAGGCC CAGGGATGGC TCCAGTTGGG GATCCAGCAG GAGACCCTCT GCACATGAGG CTGGTTTACC AACATCTACT CCCTCAGGAT GAGCGTGAGC CAGAAGCAGC TGTGTATTTA AGGAAACAAG CGTTCCTGGA ATTAATTTAT AAATTTAATA AATCCCAATA TAATCCCAAA AAAAAAAAAA AAAAAATTCC TGCGGCCGCA AGGA, set forth as SEQ ID NO: 11.
12. A purified DNA molecule encoding a human cyclin dependent kinase wherein said DNA molecule encodes a protein comprising the amino acid sequence as follows:
Met Asp Gin Tyr Cys He Leu Gly Arg He Gly Glu Gly Ala His Gly
He Val Phe Lys Ala Lys His Val Glu Thr Gly Glu He Val Ala Leu Lys Lys Val Ala Leu Arg Arg Leu Glu Asp Gly Phe Pro Asn Gin Ala
Leu Arg Glu He Lys Ala Leu Gin Glu Met Glu Asp Asn Gin Tyr Val
Val Gin Leu Lys Ala Val Phe Pro His Gly Gly Gly Phe Val Leu Ala Phe Glu Phe Met Leu Ser Asp Leu Ala Glu Val Val Arg His Ala Gin
Arg Pro Leu Ala Gin Ala Gin Val Lys Ser Tyr Leu Gin Met Leu Leu
Lys Gly Val Ala Phe Cys His Ala Asn Asn He Val His Arg Asn Leu
Lys Pro Ala Asn Leu Leu He Ser Ala Ser Gly Gin Leu Lys He Ala Asp Phe Gly Leu Ala Arg Val Phe Ser Pro Asp Gly Ser Arg Leu Tyr
Thr His Gin Val Ala Thr Arg Ser Val Gly Cys He Met Gly Glu Leu
Leu Asn Gly Ser Pro Leu Phe Pro Gly Lys Asn Asp He Glu Gin Leu
Cys Tyr Val Leu Arg He Leu Gly Thr Pro Asn Pro Gin Val Trp Pro
Glu Leu Thr Glu Leu Pro Asp Tyr Asn Lys He Ser Phe Lys Glu Gin Val Pro Met Pro Leu Glu Glu Val Leu Pro Asp Val Ser Pro Gin Ala
Leu Asp Leu Leu Gly Gin Phe Leu Leu Tyr Pro Pro His Gin Arg He
Ala Ala Ser Lys Ala Leu Leu His Gin Tyr Phe Phe Thr Ala Pro Leu
Pro Ala His Pro Ser Glu Leu Pro He Pro Gin Arg Leu Gly Gly Pro
Ala Pro Lys Ala His Pro Gly Pro Pro His He His Asp Phe His Val Asp Arg Pro Leu Glu Glu Ser Leu Leu Asn Pro Glu Leu He Arg Pro Phe He Leu Glu Gly, set forth as SEQ ID NO: 12.
13. A process for the expression of a human cyclin dependent kinase protein in a recombinant host cell, comprising:
(a) transfecting the expression vector of Claim δ into a suitable host cell; and,
(b) culturing the host cells of step (a) under conditions which allow expression of the human cyclin dependent kinase protein from the expression vector.
14. An expression vector for the expression of a human cyclin dependent kinase in a recombinant host cell wherein said expression vector comprises the DNA molecule of Claim 11.
lδ. The expression vector of Claim 14 which is selected from the group consisting of pcDNA3.1:CDK10-D127N and pBBH:CDK10- D127N.
16. A purified antibody raised against a protein comprising the amino acid sequence as set forth in SEQ ID NO:3.
17. A purified antibody of claim 16 raised against a protein consisting of the amino acid sequence as set forth in SEQ ID
NO:3.
18. A purified antibody of claim 16 raised against a protein consisting of the amino acid sequence consisiting of SEQ ID NO:12.
19. A purified antibody of claim 16 raised against a peptide fragment comprising from about amino acid 301 to amino acid 32δ ofSEQ ID NO:3.
20. A purified antibody of claim 19 raised against a peptide fragment consisting of amino acid 301 to amino acid 32δ of SEQ ID NO:3.
?
PCT/US1998/002337 1997-02-07 1998-02-06 Cyclin-dependent protein kinase WO1998035015A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002280206A CA2280206A1 (en) 1997-02-07 1998-02-06 Cyclin-dependent protein kinase
JP53492298A JP2001511015A (en) 1997-02-07 1998-02-06 Cyclin-dependent protein kinase
EP98906202A EP0972011A4 (en) 1997-02-07 1998-02-06 Cyclin-dependent protein kinase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3785597P 1997-02-07 1997-02-07
US60/037,855 1997-02-07
GB9707491.8 1997-04-14
GBGB9707491.8A GB9707491D0 (en) 1997-04-14 1997-04-14 Cyclin-dependent protein kinase

Publications (1)

Publication Number Publication Date
WO1998035015A1 true WO1998035015A1 (en) 1998-08-13

Family

ID=26311373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/002337 WO1998035015A1 (en) 1997-02-07 1998-02-06 Cyclin-dependent protein kinase

Country Status (4)

Country Link
EP (1) EP0972011A4 (en)
JP (1) JP2001511015A (en)
CA (1) CA2280206A1 (en)
WO (1) WO1998035015A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036118A2 (en) * 1998-12-16 2000-06-22 Chiron Corporation HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
WO2000073469A2 (en) * 1999-05-28 2000-12-07 Sugen, Inc. Protein kinases
WO2009063175A1 (en) * 2007-11-13 2009-05-22 The Institute Of Cancer Research; Royal Cancer Hospital Methods for determining resistance to cancer therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MORGAN D. O.: "THE DYNAMICS OF CYCLIN DEPENDENT KINASE STRUCTURE.", CURRENT OPINION IN CELL BIOLOGY., CURRENT SCIENCE, LONDON., GB, vol. 08., no. 06., 1 December 1996 (1996-12-01), GB, pages 767 - 772., XP002910839, ISSN: 0955-0674, DOI: 10.1016/S0955-0674(96)80076-7 *
PINES J.: "CELL CYCLE: REACHING FOR A ROLE FOR THE CKS PROTEINS.", CURRENT BIOLOGY, CURRENT SCIENCE, GB, vol. 06., no. 11., 1 November 1996 (1996-11-01), GB, pages 1399 - 1402., XP002910838, ISSN: 0960-9822, DOI: 10.1016/S0960-9822(96)00741-5 *
See also references of EP0972011A4 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036118A2 (en) * 1998-12-16 2000-06-22 Chiron Corporation HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
WO2000036118A3 (en) * 1998-12-16 2000-11-16 Chiron Corp HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
JP2003524389A (en) * 1998-12-16 2003-08-19 カイロン コーポレイション Human cyclin dependent kinase (hPNQALRE)
US7250256B2 (en) 1998-12-16 2007-07-31 Chiron Corporation Human cyclin-dependent kinase (hPNQALRE)
EP1961813A3 (en) * 1998-12-16 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
US7566559B2 (en) 1998-12-16 2009-07-28 Novartis Vaccines And Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
JP2010162036A (en) * 1998-12-16 2010-07-29 Novartis Vaccines & Diagnostics Inc HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
US7855058B2 (en) 1998-12-16 2010-12-21 Novartis Vaccines And Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
WO2000073469A2 (en) * 1999-05-28 2000-12-07 Sugen, Inc. Protein kinases
WO2000073469A3 (en) * 1999-05-28 2001-11-29 Sugen Inc Protein kinases
WO2009063175A1 (en) * 2007-11-13 2009-05-22 The Institute Of Cancer Research; Royal Cancer Hospital Methods for determining resistance to cancer therapy

Also Published As

Publication number Publication date
EP0972011A1 (en) 2000-01-19
EP0972011A4 (en) 2003-04-16
JP2001511015A (en) 2001-08-07
CA2280206A1 (en) 1998-08-13

Similar Documents

Publication Publication Date Title
EP0690876B1 (en) Protein kinases
US5532151A (en) G protein-coupled receptor kinase GRK6
US6030788A (en) Cyclin-dependent protein kinase
US8916379B2 (en) Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof
WO1998035015A1 (en) Cyclin-dependent protein kinase
US20020015998A1 (en) Novel G protein-coupled receptors
AU734736B2 (en) Nucleic acid sequences that encode a cell growth regulatory protein and uses thereof
US6348341B1 (en) Human p101 regulatory polypeptide
AU5333999A (en) Identification and functional characterization of a novel ribosomal s6 protein kinase
CZ318997A3 (en) Genes encoding polypetides of lymphocytar interferon regulation factor
US6210916B1 (en) Rec 2 kinase
US7060463B2 (en) DNA molecules encoding Macaca mulatta androgen receptor
US20030096348A1 (en) DNA molecules encoding mammalian nuclear receptor protein, nNR5
US20030022311A1 (en) Human CIS protein
WO1997020573A1 (en) Growth factor receptor-binding protein 2 homolog
US5840536A (en) Growth factor receptor-binding insulin receptor
WO1997044347A1 (en) Human cis protein
CA2401852C (en) Dna molecules encoding a glutamate-gated chloride channel in drosophila melanogaster
CA2395378A1 (en) Dna molecules encoding human nhl, a dna helicase
WO1998001475A1 (en) Growth factor receptor-binding insulin receptor
AU3562099A (en) Assay methods for modulators of hematopoietic cell phosphatase
US20040106784A1 (en) Socs (suppressor of cytokine signaling)
WO2000065025A2 (en) Dna molecules encoding human endothelin converting enzyme 3
JP2002233366A (en) Human deoxycytidine kinase 2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998906202

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2280206

Country of ref document: CA

Ref country code: CA

Ref document number: 2280206

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 534922

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998906202

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998906202

Country of ref document: EP